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Identification & Evaluation of DNA Ligase Inhibitors: Predicting the Binding
of Small Molecules to the DNA Binding Domain by Molecular Modeling

by

Timothy Richard Lloyd Howes
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ABSTRACT

The phosphodiester backbone of DNA is maintained by DNA ligases. In
human cells, there are three genes that encode DNA ligase polypeptides with
distinct but overlapping functions. A series of small molecule inhibitors of human
DNA ligases were previously identified using a rational structure-based approach.
Three of these inhibitors, L82, a DNA ligase I selective inhibitor, and L67, an
inhibitor of DNA ligases I and III, and L189, an inhibitor of all three human DNA
ligases, have related structures. Here I present and characterize L82-G17 a nextgeneration ligase I specific inhibitor. L82-G17 is a potent ligase I uncompetitive
inhibitor that is shown to act both biochemically and in cell culture models.
Furthermore, the binding site for L82 and L82-G17 has been identified via
molecular modeling, and verified through mutagenesis.
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CHAPTER 1

Introduction

Structure and Function of DNA Ligases
Since DNA polymerases only synthesize DNA from 5’ to 3’, one of the two
antiparallel strands of duplex DNA must be synthesized discontinuously as a
series of short Okazaki fragments that are then be joined by a DNA ligase to
generate an intact strand. In 1967, several laboratories identified DNA ligase
activity in extracts from both uninfected E. coli cells and E. coli cells infected with
bacteriophage T4 (Lehman 1974). The following year DNA ligase activity was
described in extracts from mammalian cells (Soderhall and Lindahl 1976).
Notably, the Escherichia coli DNA ligase is NAD+-dependent whereas the
bacteriophage and mammalian DNA ligases are ATP-dependent (Lehman 1974,
Soderhall and Lindahl 1976). Subsequent studies have revealed the existence of
both NAD+- and ATP-dependent DNA ligases in prokaryotes. In contrast,
eukaryotic and viral DNA ligases are almost exclusively ATP-dependent
(Tomkinson, Vijayakumar et al. 2006, Ellenberger and Tomkinson 2008).

Apart from utilizing a different nucleotide co-factor, the reaction
mechanisms of NAD+- and ATP-dependent are identical. DNA ligases initially
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react with the nucleotide co-factor to form a covalent DNA ligase-adenylate
complex in which the AMP moiety is linked to a specific lysine residue via a
phosphoramidite bond. When the DNA ligase-adenylate engages a DNA nick
with 3’ OH and 5’ phosphate termini, it transfers the AMP group to the 5’
phosphate, forming a covalent DNA adenylate intermediate. Finally, the nonadenylated DNA ligase interacts with the DNA-adenylate, catalyzing
phosphodiester bond formation and release of AMP as a result of nucleophilic
attack on the 5’ DNA adenylate by the 3’ OH group.

The first eukaryotic DNA ligase genes were identified in screens for cell
division cycle mutants in the yeasts, Saccharomyces cerevisiae and
Schizosaccharomyces pombe (Nasmyth 1977, Johnston and Nasmyth 1978).
The DNA ligases encoded by the CDC9 gene in Saccharomyces cerevisiae and
the CDC17 gene in Schizosaccharomyces pombe are required for cell viability
because of their essential role in DNA replication. Biochemical and
immunological characterization of DNA ligase activity in mammalian cell extracts
provided the first evidence that eukaryotes contain more than one species of
DNA ligase (Soderhall and Lindahl 1976). The presence of more than one
species of DNA ligase suggested that these enzymes may have distinct cellular
functions. My work, presented here focuses on the development of small
molecule inhibitors of human DNA ligases, with a focus on human DNA ligase I.
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Eukaryotic DNA ligase genes

As mentioned above, the DNA ligases encoded by the CDC9 and CDC17
genes of Saccharomyces cerevisiae and Schizosaccharomyces pombe,
respectively, were the first eukaryotic DNA ligases to be identified (Nasmyth
1977, Johnston and Nasmyth 1978). Human cDNAs that complemented the
temperature sensitive phenotype of a yeast cdc9 strain were isolated from a
human cDNA library (Barnes, Johnston et al. 1990). Subsequent DNA
sequencing revealed that these cDNAs encoded a polypeptide that is highly
homologous with the yeast DNA ligases and contained sequences that were
identical to those of peptides from
purified mammalian DNA ligase I
(Barnes, Johnston et al. 1990).
Thus, human DNA ligase I and the
yeast DNA ligases are functional
homologs that belong to the
eukaryotic DNA ligase I family.

Two other mammalian
genes that encode DNA ligases,
LIG3 and LIG4, have been
identified (Chen, Tomkinson et al.
Table 1. Functional redundancies of
human DNA ligases

1995, Wei, Robins et al. 1995).
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Homologs of the LIG4 gene have been found in all eukaryotes, whereas LIG3
has been found in some, but not all, eukaryotes (Ellenberger and Tomkinson
2008, Simsek and Jasin 2011). That LIG1 null cells and cells lacking nuclear
LigIII are both viable indicates a significant degree of functional redundancy
between these two enzymes in nuclear DNA metabolism (Table 1) (Tomkinson,
Howes et al. 2013). In contrast, DNA ligase III (LigIII) has been shown to be
essential for mitochondrial DNA (mtDNA) replication and repair in an XRCC1independent fashion. However, mitochondrial LigIII function can be replaced by
mitochondrially-targeted heterologous DNA ligases, including LigI, or even the
NAD+-dependent LigA of E. coli (Simsek, Furda et al. 2011).

The DNA ligases encoded by the three LIG genes share a conserved
catalytic region that is flanked by unrelated amino- and/or carboxyl-terminal
regions. There is compelling evidence that interactions with specific protein
partners mediated by these unique regions flanking the catalytic domain direct
the participation of the DNA ligases in different DNA transactions (Ellenberger
and Tomkinson 2008). An enzyme activity previously designated as DNA ligase II
was later shown to be a proteolytic fragment of DNA ligase III (Chen, Tomkinson
et al. 1995).

DNA ligase I; molecular genetics and cell biology

The gene encoding DNA ligase I, LIGI, which spans 58kb, is located on
chromosome 19q13.2-13.3, and is made up of 28 exons
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Figure 1. Human DNA ligases
The three human ligase genes encode several polypeptides. Each human ligase
contains a DNA binding domain (DBD, red) as well as a catalytic core, which consists of
an adenylation domain (AdD, green) and an oligomer binding domain (OBD, yellow).
The catalytic core is common to all DNA ligases, as well as mRNA capping enzymes.
Each DNA ligase III isoform possesses an N-terminal zinc finger (orange) that aids in
DNA binding. Ligases III and IV also have a “breast and ovarian cancer susceptibility
protein-1 C-terminal” (BRCT, green) domain. Mitochondrial LigIII has a mitochondrial
localization signal (MLS, cyan), while LigI and LigIII have a nuclear localization signal
(NLS, blue). In addition to the NLS, the unstructured N-terminal region of LigI also
contains a replication factory targeting sequence (RFTS, grey), also known as the PIP
box (PCNA-interacting peptide). Furthermore, several phosphorylation sites are located
in the unstructured N-terminal region of LigI. The active site lysine, which binds AMP,
has been indicated for each ligase, as well as each of the six conserved motifs. Finally,
the two residues identified as mutated in the only reported case of LigI deficiency, Glu
566 and Arg 771, are indicated (Howes and Tomkinson 2012).
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(Barnes, Tomkinson et al. 1992, Noguiez, Barnes et al. 1992). The
increased expression of the LIG1 gene when quiescent cells are induced to
proliferate and the increased levels of DNA ligase I protein and activity in
proliferating cells and tissues, implicated DNA ligase I in DNA replication
(Soderhall and Lindahl 1976, Petrini, Huwiler et al. 1991). This linkage was
strengthened by studies showing that DNA ligase I co-localized with replication
foci in S phase cells (Lasko, Tomkinson et al. 1990). Distinct amino acid
sequences within the non-catalytic N-terminal region of DNA ligase I function as
nuclear localization (NLS) and replication foci targeting sequences (Fig. 1)
(Montecucco, Savini et al. 1995, Cardoso, Joseph et al. 1997). The mechanism
underlying the recruitment of DNA ligase I to replication foci is described below.

A single case of human DNA ligase I-deficiency has been described. This
individual, whose symptoms included impaired growth, delayed development,
recurrent ear and chest infections and lymphoma, died at age 19 as result of
complications following a chest infection (Webster, Barnes et al. 1992).
Sequencing of genomic DNA revealed the presence of two different mutant lig1
alleles. The maternally inherited lig1 allele encodes a DNA ligase polypeptide
with reduced catalytic activity whereas the other mutant allele, whose origin is not
known, encodes a DNA polypeptide with essentially no catalytic activity. In both
mutant lig1 alleles, the DNA sequence change results in a single amino acid
substitution within the conserved catalytic region of DNA ligase I (Barnes,
Tomkinson et al. 1992). The locations of the amino acid changes are described
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in the section below. Primary (46BR) and SV40-immortalized (46BR.1G1)
fibroblasts established from the DNA ligase I-deficient individual exhibit defective
joining of Okazaki fragments and sensitivity to a wide range of DNA damaging
agents, particularly DNA alkylating agents (Teo, Arlett et al. 1983). Both mutant
lig1 alleles are present in the primary fibroblasts, whereas, only the maternally
inherited allele is present in the SV40-immortalized (46BR.1G1) fibroblasts. It
appears that the maternal lig1 allele is responsible for the patient’s symptoms
and the phenotype of the cell lines (Barnes, Tomkinson et al. 1992). As
expected, both the DNA replication and repair defects of the 46BR.1G1
fibroblasts are complemented by expression of wild type DNA ligase I (Levin,
McKenna et al. 2000). In addition, a DNA ligase I-deficient Arabidopsis plant cell
line that showed severe growth defects, as well as delayed repair of single and
double strand breaks has been described (Waterworth, Kozak et al. 2009).

Although the levels of DNA ligase I protein and activity are reduced by
about 50% and 90%, respectively in the 46BR.1G1 fibroblasts compared with
SV40-immortalized fibroblasts from a normal individual, there are no significant
differences in cell cycle progression despite the defect in converting Okazaki
fragments into high molecular weight DNA (Barnes, Tomkinson et al. 1992). In
fact, results of pulse-labeling studies indicate that the majority of Okazaki
fragments are degraded rather than ligated (Henderson, Arlett et al. 1985, Levin,
Vijayakumar et al. 2004). Thus, it appears that, when DNA ligase I is not
available to ligate the nick between adjacent Okazaki fragments, the downstream
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fragment is displaced by DNA synthesis and then degraded. This model predicts
that the lagging strand in 46BR.1G1 fibroblasts is synthesized as a series of
longer fragments that are joined by either the defective DNA ligase I polypeptide
or one of the other DNA ligases.

Based on the results of genetic studies in the yeasts Saccharomyces
cerevisiae and Schizosaccharomyces pombe (Nasmyth 1977, Johnston and
Nasmyth 1978), it was expected that the mammalian LIG1 gene would be
essential. In accord with this prediction, lig1 null mouse embryonic stem cells
could only be obtained when full length wild type DNA ligase I cDNA was
ectopically expressed (Petrini, Xiao et al. 1995). Surprisingly, lig1 null embryos
generated by crossing heterozygous mice were detectable until day 16 (Bentley,
Selfridge et al. 1996, Bentley, Harrison et al. 2002). Furthermore, it was possible
to establish lig1 null embryonic fibroblasts (MEFs) from these embryos,
demonstrating that LIG1 is not an essential gene in mouse somatic cells. Like the
human 46BR.1G1 fibroblasts, the lig1 null MEFs had a defect in converting
Okazaki fragments into high molecular weight DNA but no defect in proliferation
(Bentley, Selfridge et al. 1996, Bentley, Harrison et al. 2002). In contrast to the
46BR.1G1 fibroblasts, the lig1 null MEFs have no apparent DNA repair defect
(Teo, Arlett et al. 1983, Bentley, Selfridge et al. 1996, Bentley, Harrison et al.
2002). There are also lig1 null mouse CH12F3 cells, in which exons 18-19 are
removed, resulting in a frameshift in the LIG1 which renders the protein nonfunctional. While these cells were also shown not to have an increased sensitivity
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to DNA damaging agents such as cisplatin and camptothecin, they were more
sensitive to methyl methane-sulfonate (Han, 2014).

The presence of additional DNA ligases in mammals encoded by the LIG3
gene provides a possible explanation as to why the LIG1 gene homolog, CDC9,
is essential for cell viability in yeast but not in mammals. For example, DNA
ligase III and its partner protein XRCC1 are recruited to participate in the repair
of DNA single strand breaks by an interaction with the poly(ADP-ribosylated)
version of poly(ADP-ribose) polymerase 1 (PARP-1), an abundant nuclear
protein that binds to and is activated by DNA single strand breaks (Okano, Lan et
al. 2003, Okano, Lan et al. 2005). The defect in Okazaki fragment processing
caused by DNA ligase I deficiency is likely to result in relatively long-lived, singlestrand interruptions on the lagging strand. It is possible that these breaks are
recognized and joined by the PARP-1/DNA ligase III single strand break repair
pathway. The hyper sensitivity of human 46BR.1G1 fibroblasts (Lehmann, Willis
et al. 1988) to a PARP inhibitor is consistent with the single strand break repair
pathway joining single strand breaks between Okazaki fragments that remain
after lagging strand DNA synthesis. It is important to note that recent publications
have established that LigIII enable cells with reduced levels or absence of DNA
ligase I to proliferate (Le Chalony, Hoffschir et al. 2012). However, LigIV cannot
substitute for LigI to ligate Okazaki fragments, as LIG1 and LIG3 dual knockouts
in chicken DT40 cells are synthetic lethal (Arakawa and Iliakis 2015).
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A mouse knock-in model that reiterates the mutant allele of DNA ligase I
that is expressed in the human SV-40 immortalized 46BR.1G1 cells has been
generated. These animals are small and have hematopoietic defects (Harrison,
Ketchen et al. 2002). Other notable features include increased genomic instability
and an increased incidence of epithelial tumors (Harrison, Ketchen et al. 2002).
As with the lig1 null MEFs, the MEFs harboring the equivalent mutation to that in
the human SV-40 immortalized 46BR.1G1 fibroblasts have a defect in replication
but not repair, suggesting that the increased genome instability and cancer
incidence is due to accumulation of abnormal replication intermediates (Harrison,
Ketchen et al. 2002). Together, these studies indicate that DNA ligase I has a
more important role in DNA repair in human than murine cells (Teo, Arlett et al.
1983, Harrison, Ketchen et al. 2002) and suggest that the relative contribution of
DNA ligase III-dependent repair may be greater in murine cells compared with
human cells.

Structure of the Human DNA Ligase I Protein

The 919 amino acid polypeptide encoded by human DNA ligase I cDNA
has a highly asymmetric shape, which results in abnormal behavior during
density gradient sedimentation and gel filtration experiments (Tomkinson, Lasko
et al. 1990). Using limited proteolysis, it was found that catalytic activity resides
within a relatively protease-resistant C-terminal fragment of about 78 kilo Daltons
(kDa) whereas the N-terminal fragment is extremely protease sensitive, indicative
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of an unstructured region (Tomkinson, Lasko et al. 1990). Notably, this Nterminal region is likely to have an extended, flexible conformation because it
contains a large number of proline residues (Barnes, Johnston et al. 1990). In
addition, the high proline content of DNA ligase I (approximately 9%) results in
abnormally mobility during SDS-polyacrylamide gel electrophoresis, such that
DNA ligase I an apparent molecular mass of 125 kDa compared with the actual
molecular weight of 102,000 (Tomkinson, Lasko et al. 1990).

The catalytic region of DNA ligase I contains six motifs that are conserved
among the nucleotidyl transferase family, including mRNA capping enzymes,
RNA ligases, and DNA ligases (Shuman and Schwer 1995). Motif I contains the
active site lysine residue to which the AMP (or GMP) residue is attached via a
covalent phosphoramidite bond. This residue was initially identified by
determining the sequence of an adenylylated tryptic peptide from bovine DNA
ligase I (Tomkinson, Totty et al. 1991). Using this sequence, it was possible to
predict the position of the putative active site lysine residues in DNA ligases,
RNA ligases, and mRNA capping enzymes. As expected, substitution of Lys568,
the lysine residue that is covalently linked to the AMP moiety in human DNA
ligase I, prevents formation of the enzyme-AMP complex and consequently
abolishes enzymatic activity (Kodama, Barnes et al. 1991, Tomkinson, Totty et
al. 1991). One of the mutant alleles in the DNA ligase I-deficient individual
encodes a polypeptide with has a lysine residue in place of a glutamic acid at
position 566 (Barnes, Tomkinson et al. 1992). This amino acid change two
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residues away from the active site lysine markedly reduces formation of the
enzyme-AMP intermediate (Kodama et al, 1991), indicating that this mutant allele
encodes a polypeptide with very little or no activity.

The first nucleotidyl transferase structure to be determined was that of the
DNA ligase encoded by bacteriophage T7 (Subramanya, Doherty et al. 1996).
This was shortly followed by the characterization of the RNA-capping enzyme
from PCBV-1 (Hakansson, Doherty et al. 1997). These structures revealed the
existence of two domains, an adenylation/guanylation domain, which contains
conserved motifs I through V, and an oligomer binding-fold (OB) domain (OBD)
containing motif VI (Fig. 1). In 2004, Pascal et al. successfully crystallized the
catalytic C-terminal region of DNA ligase I (residues 233-919) bound to a nicked
DNA substrate (Pascal, O'Brien et al. 2004). This structure revealed several
novel features. Firstly, it showed that nicked DNA is encircled by DNA ligase I
during catalysis, suggesting that the catalytic domain undergoes a large
conformational change when it engages a nick. Secondly, it showed that the
catalytic region of the larger eukaryotic DNA ligases contains a DNA binding
domain in addition to the adenylation and OB-fold domains that make up the
catalytic core. Thus, the adenylation/guanylation and OB-fold domains constitute
the conserved catalytic core of nucleotidyl transferases with the DNA binding
domain (DBD) being a characteristic feature of eukaryotic DNA ligases (Pascal,
O'Brien et al. 2004).
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The DNA binding domain of DNA ligase I, which spans residues 262 to
534, folds into 12 α-helices that exhibit a two-fold symmetry (Pascal, O'Brien et
al. 2004). Due to the symmetry of the DBD, the interaction with DNA occurs via
one tight reverse turn of two α-helices and an extended loop formation. This
arrangement of the loop and helices creates a relatively flat surface of
approximately 2000 Å2 that interacts almost exclusively with the phosphodiester
backbone of the DNA substrate. The DBD interacts with the minor groove of the
DNA backbone on both sides of the nick, explaining how DNA ligase I binds to
DNA in a sequence-independent binding manner and why chemicals that bind to
the minor groove of DNA, such as distamycin, inhibit DNA ligase activity
(Montecucco, Fontana et al. 1991). Notably, the DBD stimulates the weak DNA
joining activity of the DNA ligase I catalytic core containing the AdD and OBD
when added in trans, indicating that contacts between the DBD and both AdD
and the OBD observed in the crystal structure stabilize the folding of the catalytic
core around the DNA nick (Pascal, O'Brien et al. 2004).

The DNA ligase I adenylation domain, which spans from residue 535 to
747, contains conserved motifs I, III, IIIa, IV and V. These five motifs contribute to
the surface of nucleotide binding pocket. Tryptophan 742, of motif V, provides cofactor specificity by sterically excluding GTP. Furthermore, Arg 573 and Glu 621,
of motifs I and III, respectively, stabilize the hydroxyl groups on the ribose sugar
of AMP via hydrogen bonding interactions (Pascal, O'Brien et al. 2004). As
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mentioned above, one of the two
mutant LIG1 alleles identified in
the individual with DNA ligase I
deficiency encodes a polypeptide
in which Glu 566, of motif I, is
replaced by a lysine residue
(Barnes, Tomkinson et al. 1992).
From the structure of DNA ligase
I, it is evident that Glu 566
contributes to the specific
interaction with ATP by forming a
hydrogen-bond with the N6 of the

Figure 2. DNA ligation is a three-step
process

adenine moiety (Pascal, O'Brien
First, the DNA ligase binds and hydrolyses
ATP, pyrophosphate is released and a AMP
is bound to DNA ligase. Second, the
adenosine monophosphate is transferred to
the 5’ phosphate of the DNA at the nick.
Finally, the ligase catalyzes the
phosphodiester bond formation by
nucleophilic attack by the 3’ hydroxide. Both
AMP and the ligase dissociate from the DNA
(Howes and Tomkinson 2012).

et al. 2004). Replacement of Glu
566 with a positively charged
lysine residues disrupts this,
providing an explanation as to
why the mutant polypeptide is
defective in the first step of the

ligation reaction, formation of the covalent enzyme-adenylate intermediate (Fig.
2).
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The major structural feature of the OB-fold domain is a β-barrel and,
similar to the other two domains, it also interacts with the minor groove of the
DNA (Pascal, O'Brien et al. 2004). Contacts between AdD and OBD are critical
for correctly positioning these domains when they engage a DNA nick. During
catalysis, the AdD forms a salt bridge with the OBD via Asp 570 and Arg 871,
stabilizing the ligase catalytic domains in a conformation in which they fully
encircle the DNA nick. This positioning of the AdD and OBD creates a surface
that binds to and distorts the nicked DNA. Notably, the phenylalanine residues at
positions 635 and 872 of the AdD and OBD, are forced into the minor groove
both 3’ and 5’ to the nick. As a result of these interactions, the DNA duplex
upstream of the nick duplex assumes an A-form structure as the nick is opened
up for ligation (Pascal, O'Brien et al. 2004). Notably, the DNA binding site
downstream of the nick is specific for B-form DNA, explaining why ligase I is not
active on nicks within A-form duplexes formed by RNA duplexes and RNA-DNA
hybrids (Pascal, O'Brien et al. 2004). This ability to discriminate against duplexes
containing ribonucleotides 5’ to the nick presumably prevents premature joining
of Okazaki fragments before the RNA primer has been removed. The maternally
inherited mutant LIG1 allele in the individual with DNA ligase I-deficiency
encodes a polypeptide in which the arginine 771 within the OBD is replaced by a
tryptophan residue (Fig. 1) (Barnes, Tomkinson et al. 1992). This mutant enzyme
has markedly reduced catalytic activity and is, as expected, defective in step 2 of
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the ligation reaction, transfer of the AMP moiety from the ligase to the 5’
phosphate termini of the DNA nick (Prigent, Satoh et al. 1994).

Although eukaryotic DNA ligase I has not been crystallized in the absence
of nicked DNA, others DNA ligases have been crystalized in the absence of DNA
substrate; the structure of an ATP-dependent DNA ligase from the archaeal
organism Sulfolobus solfataricus has been determined in the absence of DNA
(Pascal, Tsodikov et al. 2006). The catalytic region of the archaeal enzyme has
the same three domain organization as eukaryotic DNA ligases but, in the
absence of DNA, the three domains are arranged in an extended conformation.
The major difference between the extended and closed conformations of the
three domains is the position of the OBD domain relative to the other two
domains (Pascal, Tsodikov et al. 2006). The OBD undergoes a large change in
conformation during the nicked DNA-dependent transition from the extended to
the closed form with interactions between the OBD and DBD playing key roles in
stabilizing the closed form. Based on structures of smaller DNA ligases, it
appears likely that the OBD also undergoes conformational changes when the
enzyme interacts with ATP to form the enzyme-adenylate, possibly reorienting
the OBD to expose a DNA binding surface (Subramanya, Doherty et al. 1996,
Odell, Sriskanda et al. 2000).

While the unstructured N-terminal region of DNA ligase I is dispensable for
catalytic activity in vitro, it was presumed to be required for protein-protein
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interactions in vivo (Petrini, Xiao et al. 1995, Mackenney, Barnes et al. 1997).
This region contains a bipartite nuclear localization signal located between
residues 111 and 179, and a sequence that is required for targeting to replication
factories, residues 2 to 9 (Montecucco, Savini et al. 1995, Cardoso, Joseph et al.
1997). In addition, the N-terminal region is phosphorylated on several
serine/threonine residues by casein kinase II and cyclin-dependent kinases
during cell cycle progression (Prigent, Lasko et al. 1992, Frouin, Montecucco et
al. 2002, Ferrari, Rossi et al. 2003) (Fig. 1). This results in a hyperphosphorylated form of DNA ligase I in M phase cells. It appears likely that these
phosphorylation events regulate the participation of DNA ligase I in DNA
replication because phosphorylation site mutants fail to correct the DNA
replication defect of DNA ligase I-deficient 46BR cells (Soza, Leva et al. 2009,
Vijayakumar, Dziegielewska et al. 2009) (Peng et al.).

Human DNA Ligase I Protein-Protein Interactions

Proteins are directed to participate in complex DNA transactions such as
DNA replication by specific protein-protein interactions. Proliferating cell nuclear
antigen (PCNA), the eukaryotic homotrimeric DNA sliding clamp that functions as
a processivity factor for the replicative DNA polymerases, was the first DNA
ligase I-interacting protein to be identified (Levin, Bai et al. 1997). Residues 2 to
9 within the non-catalytic N-terminal region of DNA ligase I constitute the major
PCNA binding site within DNA ligase I (Montecucco, Rossi et al. 1998). Notably,
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this same sequence, which is homologous to a PCNA-interacting protein motif, or
“PIP box” which has been identified in many proteins, is required for the
recruitment of DNA ligase I to replication factories (Montecucco, Rossi et al.
1998). Amino acid changes that disrupt PCNA binding abolish both the
recruitment of DNA ligase I to replication factories and the correction of the DNA
replication defect in 46BR.1G1 cells, demonstrating the critical role of this
interaction in the sub-nuclear targeting of DNA ligase I and the efficient joining of
Okazaki fragments (Montecucco, Rossi et al. 1998, Levin, McKenna et al. 2000).

The PIP box motif binds to the interdomain connector loop of PCNA
(Vijayakumar, Chapados et al. 2007), suggesting that, when the flexible Nterminal region of DNA ligase I initially binds to the interdomain connector loop of
PCNA trimer, the catalytic region remains in an extended conformation (Pascal,
Tsodikov et al. 2006). Notably, DNA ligase I stably interacts with PCNA trimers
that are topologically linked to duplex DNA but only one molecule of DNA ligase I
is bound per PCNA trimer (Levin, Bai et al. 1997). This suggests that the other
potential binding sites are occluded either because of dynamic conformational
changes in DNA ligase I as a consequence of its flexible, extended structure or
because the initial docking of DNA ligase I with a PCNA trimer via the PIP box
facilitates lower affinity interactions that extend the protein-protein interaction
interface. In support of this latter idea, the DBD binds weakly to the subunitsubunit interface region of homotrimeric PCNA (Song, Pascal et al. 2009).
Interestingly, the DBD also mediates the interaction with Rad9-Rad1-Hus1, a
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heterotrimeric DNA sliding clamp involved in cell cycle checkpoints (Song, Pascal
et al. 2009), and heterotrimeric PCNA from Sulfolobus solfataricus (Pascal,
Tsodikov et al. 2006). Given the similarity in size and shape between the PCNA
ring and the ring structure formed when the catalytic region of DNA ligase I
engages a DNA nick, the PCNA ring may facilitate the transition of the catalytic
region of DNA ligase I from the extended conformation to the compact ring
structure. It has been proposed that the DBD, which provides the majority of the
DNA binding affinity, serves as a pivot during this transition after initial docking
via the PIP box. Unlike studies on the interaction between DNA ligase I and the
heterotrimeric Rad9-Rad1-Hus1 checkpoint DNA sliding clamp (Wang, LindseyBoltz et al. 2006, Song, Levin et al. 2007), there are contradictory reports as to
whether the interaction with PCNA stimulates nick-joining by DNA ligase I (Levin,
Bai et al. 1997, Tom, Henricksen et al. 2001, Levin, Vijayakumar et al. 2004).

DNA ligase I also functionally interacts with two other DNA replication
proteins, replication protein A (RPA), a heterotrimeric complex that binds to
single stranded DNA (Ranalli, DeMott et al. 2002), and replication factor C
(RFC), a heteropentameric complex that loads PCNA onto DNA (Levin,
Vijayakumar et al. 2004). Although a direct physical interaction between RPA and
DNA ligase I has not been demonstrated, RPA specifically stimulates the rate of
catalysis by DNA ligase I (Ranalli, DeMott et al. 2002). In contrast to RPA, RFC
inhibits DNA joining by DNA ligase I (Levin, Vijayakumar et al. 2004). This
interaction and inhibition, which involves the large subunit of RFC, p140, is
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abolished by replacement of the four phosphorylation site serines in DNA ligase I
with glutamic acid residues (Vijayakumar, Dziegielewska et al. 2009). More
recently, phosphorylation of serine 51 was specifically identified as regulating the
LigI-RFC interaction. The S51D phosphomimetic mutant LigI failed to stably
interact with RFC. Furthermore, 46BR.1G1 cells expressing a S51A DNA ligase I
were more resistant to alkylating agent MMS than either 46BR.1G1 cells that
expressed S51D or cells transfected with an empty vector.

Notably, the inhibition of DNA ligase I by RFC can be alleviated by
inclusion of PCNA in the reaction, providing that DNA ligase I has a functional
PIP box (Vijayakumar, Dziegielewska et al. 2009). Unlike the interaction with
RFC, DNA ligase I binding to PCNA is not modulated by phosphorylation
(Vijayakumar, Dziegielewska et al. 2009). Thus, the failure of the phosphorylation
site mutant of DNA ligase I to complement the replication defect in DNA ligase Ideficient cells may be due to the disrupted interaction with RFC (Vijayakumar,
Dziegielewska et al. 2009). Although these studies indicate that physical and
functional interactions among DNA ligase I, RFC and PCNA are critical for DNA
replication, the mechanisms by which these interactions contribute to Okazaki
fragment processing and joining are not fully understood.
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DNA Ligase Inhibitors

Identifying Potential DNA Ligase Inhibitors

Inhibitors of DNA repair are emerging as a potent new class of
chemotherapeutics; in recent years, several groups around the world have
become interested in developing and using DNA ligase inhibitors as anti-cancer
agents (Kotnis and Mulherkar 2014). While clinically relevant compounds, such
as distamycin and its derivatives, have been shown to inhibit DNA ligases, they
are highly toxic, and non-specific, as their action is mediated by binding to the
minor groove of DNA, not DNA ligase itself (Montecucco, Fontana et al. 1991).
Efforts to identify DNA ligase inhibitors through in vitro screens of natural
products have met with limited success (Sangkook, Ik-Soo et al. 1996) compared
with in silico screening methods. In 2008, ten novel small molecules (Fig. S1)
that function to inhibit mammalian DNA ligases were reported. These were
identified via a computer aided drug design (CADD) screen for compounds that
were predicted to bind to the DBD of human DNA ligase I (Zhong, Chen et al.
2008). The DBD was chosen because the adenylation and oligo-binding domains
are common to all nucleotidyl transferase enzymes (Doherty and Suh 2000,
Pascal, O'Brien et al. 2004). Additionally, the DBD is less conserved than the
AdD/OBD catalytic core, increasing the likelihood finding selective inhibitors for
the human DNA ligases.
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A potential binding pocket in the DNA ligase I DBD formed between three
residues, His 337, Arg 449, and Gly 453 was selected as the target site for the in
silico screening. The presence of a small molecule in this binding pocket, which
is created by the loops between helices 5 and 6, and helices 12 and 13 on the
DNA binding surface of the DBD, (Pascal, O'Brien et al. 2004, Zhong, Chen et al.
2008) was predicted to block binding to nicked DNA, thereby inhibiting ligation.
More than one million compounds were screened for their ability to physically fit
within the target binding pocket using the crystal structure of human DNA ligase I
(PDB ID: 1X9N) (Pascal, 2004, Berman, 2000). Preliminary screening returned
approximately 50,000 compounds that were predicted to bind in this pocket
based on total interaction energy. This list was further refined by testing the
molecules against four different potential conformations of the DNA ligase I DBD
determined by molecular dynamic simulations. The 50,000 molecules were
assessed based on the strength of their electrostatic interactions within the new
conformations of the target binding pocket. Compounds that did not fit certain
criteria called “Lipinski’s rule of 5” such as exceeding five rotatable bonds, or
number of ring structures were eliminated (Lipinski 2000). Finally, to ensure
maximal chemical diversity, these compounds were organized based on their
chemical properties. A total of 233 compounds were identified and then assayed
for their ability to inhibit DNA ligase I, yielding the 10 compounds with activity
against DNA ligase I described in more detail below (Zhong, Chen et al. 2008).
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Characterizing DNA Ligase Inhibitors

Of the 233 compounds identified by the in silico screen, named L1 through
to L233, 192 were found to be commercially available. These were acquired and
assayed for their ability to inhibit human DNA ligase I. To identify any compounds
that were inhibiting ligation non-specifically by binding to DNA, the candidates
were also tested against T4 DNA ligase, which lacks a DNA binding domain.
From this process, ten compounds that specifically inhibit DNA ligase I were
identified. While the majority of these compounds were, as expected, competitive
inhibitors, one inhibitor, L82, was uncompetitive (Zhong, Chen et al. 2008). This
was somewhat surprising, because the screen was designed to identify inhibitors
that prevent DNA binding.

The DNA ligase I inhibitors were also screened for activity against the
other human DNA ligases, revealing compounds that were also active against
the other DNA ligases. These were placed in three groups; DNA ligase I
selective; active against DNA ligase III as well as DNA ligase I; active against all
three human DNA ligases. Representatives of each group, L82, L67 and L189,
respectively were characterized further (Chen, Zhong et al. 2008). Interestingly
L67 and L189 were highly cytotoxic, whereas L82 was not (Chen, Zhong et al.
2008, Ricci, Tedeschi et al. 2009). This high toxicity of L67 has recently been
shown to be the result of inhibiting mitochondrial DNA ligase III (Sallmyr, 2016).
A separate group has described a derivative of L189, named SCR7, that appears
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may be more selective for DNA ligase IV (LigIV) (Srivastava, Nambiar et al.
2012). However, recent publications have contradicted both the reported
structure and selectivity of SCR7 (Greco, Conrad et al. 2016, Greco, Matsumoto
et al. 2016).

DNA Ligases as Biomarkers of Abnormal DNA Repair

DNA Ligase I

DNA ligases perform essential functions in DNA replication,
recombination, and repair. Therefore, increasing or decreasing the presence or
enzymatic activity of any of the ligase proteins could have a sizable impact on
these transactions. As mentioned above, there has only ever been a single DNA
ligase I-deficient individual described. Mouse studies have shown that while LIG1
null mice develop until about mid-way through embryogenesis before perishing,
LIG1 null cell lines can be established from these embryos (Bentley, Harrison et
al. 2002). From this information, we can conclude DNA ligase I is essential for
embryogenesis, but that one of the other DNA ligases can substitute for DNA
ligase I, permitting cell viability. Indeed, it may be possible for steady state
expression levels of DNA ligase I to fall significantly, without a noticeable
phenotype. However, ligase I deficiency, as observed in 46BR cells, has been
shown to trigger ubiquitylation of PCNA at lysine 107 (Das-Bradoo, Nguyen et al.
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2010). Overexpression of LigI has been linked with genomic instability and
decreased slipped-DNA repair, (Srivastava, Nambiar et al. 2012) it has also been
observed that LigI is elevated in cancer cell lines (Sun, Urrabaz et al. 2001).

DNA Ligase III

The gene that encodes DNA ligase III (LIG3) is located on chromosome
17 (Chen, Tomkinson et al. 1995). The human LIG3 gene encodes three different
isoforms of DNA ligase III, nuclear and mitochondrial forms of LigIII and a form
generated by alternative splicing, LigIII (Fig. 1). Patients with chronic
myelogenous leukemia (CML) may express the oncogene BCR-ABL, a fusion
gene that is the result of the characteristic Philadelphia translocation,
t(9;22)(q34;q11) (Hagemeijer, Bootsma et al. 1982). However, the presence of
the Philadelphia chromosome is insufficient to successfully diagnose CML, as
these features may also be present in acute lymphoblastic leukemia (Hermans,
Heisterkamp et al. 1987) as well as acute myeloid leukemia (Paietta, Racevskis
et al. 1998). Recent studies of DNA repair mechanisms in CML have shown that
highly error-prone methods of double-strand break repair may contribute to
disease progression (Sallmyr, Tomkinson et al. 2008). Double-strand DNA
breaks are widely considered to be the most potentially dangerous form of DNA
damage. The two major mechanisms of double strand break repair are
homologous recombination (HR), which is the predominant mechanism during
G2 and late S-phase, and non-homologous end-joining (NHEJ), which acts
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primarily during G0, G1, and early S-phase. HR makes use of the undamaged
sister chromatid present in G2 and late S-phase as a template for repair, and as
such, is the ideal and least error prone mechanism of double-strand break repair.
NHEJ does not have the luxury of a sister chromatid, and is therefore more error
prone than HR. This can result in errors such as small insertions or deletions at
the break site but may also join DNA ends that were previously not associated
with each other, resulting in large chromosomal rearrangements. In terms of cell
survival, this is still largely preferable to leaving double-strand breaks unrepaired
(Rassool and Tomkinson 2010).

The major HR and NHEJ pathways are not the only mechanisms for
repairing a double-strand break. Under certain circumstances, cells will resort to
alternative-NHEJ pathways, which are far more error prone and frequently
generate large deletions or chromosomal translocations (Nussenzweig and
Nussenzweig 2007). CML patients have been observed to express higher than
normal levels of the gene WRN (8p12) as well as DNA ligase III, which is the
major DNA ligase involved in Alt-NHEJ. WRN mutation is normally associated
with Werner syndrome, a disease characterized by premature aging. While CML
cells show elevated levels of DNA ligase III, two other DSB repair proteins,
Artemis and DNA ligase IV, are downregulated (Sallmyr, Tomkinson et al. 2008).
Artemis has been clearly shown to be involved with both HR and NHEJ, but not
Alt-NHEJ, (Rassool and Tomkinson 2010, De Ioannes, Malu et al. 2012) resulting
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in hypersensitivity to ionizing radiation in Artemis-deficient cell lines (De Ioannes,
Malu et al. 2012). The extent of these changes is increased in BCR-ABL
expressing CML cells that have acquired resistance to imatinib (Tobin, Robert et
al. 2013). The consequence of the changes in steady-state expression levels of
these proteins is that higher fidelity pathways of DNA double-strand break repair
are downregulated, and Alt-NHEJ becomes a major means of sealing DSB’s,
resulting in an increase in genomic mutations that may serve to drive disease
progression (Sallmyr, Tomkinson et al. 2008). Similar alterations, elevated DNA
ligase III and decreased DNA ligase IV, have been observed in breast cancers
that are both estrogen receptor (ER) and progesterone receptor (PR) negative,
as well as cancers that have developed resistance after long term exposure to
either tamoxifen or aromatase inhibitors (Tobin, Robert et al. 2012).

Increased alt NHEJ activity in breast cancer and CML cells was also
associated with elevated levels of Poly(ADP-ribose) Polymerase (PARP),
another participant in Alt-NHEJ (Rassool and Tomkinson 2010). These results
seem to indicate that the increased expression of proteins associated with AltNHEJ correlates with decreased expression of classical NHEJ proteins. This
conclusion is further supported by experiments using siRNA knockdown of
classical NHEJ component Ku70, which resulted in increased DNA ligase III
and PARP1 expression (Tobin, Robert et al. 2012). Elevated levels of PARP1
and DNA ligase III, coupled with lowered DNA ligase IV and other factors

27

involved in the major NHEJ pathway, serve as biomarkers to identify cancer cells
that rely on alternative non-homologous end-joining as their primary means of
double-strand break repair (Sallmyr, Tomkinson et al. 2008, Tobin, Robert et al.
2012, Tobin, Robert et al. 2013).

DNA ligase IV

DNA ligase IV activity was first purified from HeLa cell extracts in 1996.
The cDNA for DNA ligase IV was identified by the Lindahl laboratory, who
showed that the LIG4 gene is located on human chromosome 13 (Robins and
Lindahl 1996). Unlike the other two human DNA ligases, the DBD of LigIV starts
at the N-terminus of the DNA ligase IV polypeptide, which has two C-terminal
BRCT domains, (Fig. 1). These two tandem BRCT domains as well as the space
between these two domains has been identified as the region that interacts with
the coiled-coil of X-ray repair cross-complementing protein 4 (XRCC4)
(Grawunder, Zimmer et al. 1998). The yeast homolog of LIG4 is DNL4 (Doré,
Furnham et al. 2006). While, based on the number of submissions, LigIV has the
most crystal structures of the three human DNA ligases in the Protein Data Bank
(PDB), (Table 1) most of these structures are of small LigIV fragments (usually a
BRCT domain) and LigIV remains the only human DNA ligase yet to be
crystallized in complex with DNA (Berman, Westbrook et al. 2000).

The DNA ligase IV/XRCC4 complex is not only a core factor in the major
NHEJ pathway but is also critical for V(D)J recombination (Grawunder and Harfst
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2001). In accord with these functions, human individuals with inherited mutations
in the LIG4 gene are immunodeficient and radiation sensitive (O'Driscoll,
Cerosaletti et al. 2001). This condition, known as “LIG4 Syndrome,” (OMIM:
606593) (Hamosh, Scott et al. 2000) while not as rare as ligase I deficiency, is an
uncommon disease. Patients can have impaired growth, as well as other physical
dysmorphic features (Frank, Sharpless et al. 2000, Lee, Barnes et al. 2000,
O'Driscoll, Cerosaletti et al. 2001, Girard, Kysela et al. 2004, IJspeert, Warris et
al. 2013). Immunodeficiency, as well as radiation sensitivity is an unfortunate, if
predictable, result of impaired NHEJ. While, as noted above, reduced levels of
DNA ligase IV have been observed in cancers with increased alt NHEJ, elevated
levels of DNA ligase IV occur in other cancers, recent evidence has shown that
aberrant Wnt signaling in cancer results in increased LigIV expression and that
the elevated levels of LigIV confer radioresistance (Jun, Jung et al. 2016).

Activity of DNA Ligase Inhibitors in Preclinical Models of Human Cancer

Inhibition of DNA ligases has a high potential for toxicity; inhibitors to
NAD+-dependent ligases are undergoing evaluation as anti-bacterial agents
(Mills, Eakin et al. 2011, Stokes, Huynh et al. 2011). Moreover, in eukaryotes, the
homologue of DNA ligase I is essential for survival in yeast, (Nasmyth 1977,
Johnston and NASMYTH 1978) and deficiencies of various DNA ligases in plants
have adverse consequences (Waterworth, Kozak et al. 2009, Waterworth,
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Masnavi et al. 2010). In humans, DNA ligase III is essential for maintaining
mitochondrial DNA, with deletion of LIG3 resulting in lethality very early
inembryogenesis, (Puebla-Osorio, Lacey et al. 2006, Gao, Katyal et al. 2011)
and, as has been stated previously, DNA ligase I function is also necessary
during embryo development (Bentley, Harrison et al. 2002). Mice lacking LIG4
have been observed to die late in embryogenesis (Frank, Sekiguchi et al. 1998).
Given the evidence that here is functional redundancy among the human DNA
ligases and that, except for mitochondrial DNA ligase III, the nuclear function of
any one of the DNA ligases is not required for cell viability, it seems likely that
selective inhibition of single DNA ligase species will have limited effects on
normal tissues and cells. The cancer predisposition of rare inherited DNA repair
deficiency syndromes and the large number of mutations revealed by next
generation sequencing of sporadic cancers, suggest that abnormalities in
genome maintenance pathways is a common event and that these abnormalities
may offer the opportunity to selectively target cancer cells. Since DNA ligation
completes almost every DNA repair pathway, selective DNA ligase inhibitors may
have utility in the development of therapeutic strategies that target cancer cells.
This idea is supported by preclinical studies using a DNA ligase inhibitor to inhibit
Alt-NHEJ in CML, breast cancer and, more recently, neuroblastoma (Newman,
Lu et al. 2015).
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Breast Cancer

Breast cancer is a complex, heterogeneous disease. Endocrine therapy
has proven to be very effective in aiding the majority of patients afflicted with
breast cancer, but it does have limitations. Roughly one quarter of all breast
cancer patients express neither the estrogen receptor nor the progesterone
receptor and so are unaffected by standard frontline endocrine therapies
(Johnston and Dowsett 2003). Furthermore, these patients, who are usually
treated with non-targeted chemotherapy agents, have poor outcomes. Studies
have shown that breast cancers which are ER-/PR-, either naturally or due to long
term anti-estrogen treatment, can be induced to (re)express both ER and PR with
histone deacetylase (HDAC) inhibitors, thereby rendering them susceptible to
tamoxifen and aromatase inhibitors (Chumsri, Sabnis et al. 2011, Sabnis,
Goloubeva et al. 2011). However, HDACs regulate the expression of a large
number of genes and there may be numerous side effects of HDAC use. One
such documented effect is cardiac toxicity, and there may be others that are
presently unknown. Currently, the FDA has only approved two HDAC inhibitors,
for use treating advanced cutaneous T-cell lymphoma (Ververis and Karagiannis
2012).
The targeting of Alt NHEJ is a novel approach to selectively target ER-/PRand triple negative breast cancers. Breast cancer cell lines that have acquired
resistance to either tamoxifen or an aromatase inhibitor and ER-/PR- and triple
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negative breast cancer cell lines have up-regulated alt NHEJ factors and downregulated NHEJ factors, indicating that these cells are more dependent on alt
NHEJ for DSB repair. Notably, these cell lines are hypersensitive to combination
of PARP (ABT888) and DNA ligase III (L67) inhibitors that block alt NHEJ (Tobin,
Robert et al. 2012). While biopsies are not routinely conducted in patients with
tumors that have acquired resistance to endocrine therapy, this is not the case
for tumors that are naturally ER-/PR-, Immunohistochemical analysis of ER-/PRbiopsies consistently revealed a decrease in Ku70, and in increase in PARP1,
indicating that the alteration in DSB repair likely also occurs in tumors and that
these tumors may be responsive to the repair inhibitor combination (Tobin,
Robert et al. 2012).

Chronic Myeloid Leukemia

As has been stated previously, BCR-ABL1 positive cells, such as K562,
exhibit elevated levels of DNA ligase III and PARP1. Interestingly, both ligase
III and PARP1 were elevated to an even greater extent in an imatinib-resistant
derivative of K562 (Tobin, Robert et al. 2013). In normal cells, and even leukemia
cell lines that do not express BCR-ABL such as MO7e, derived from cells of
myeloid lineage, DNA ligase III is normally expressed. MO7e cells, which have
been modified to express stably BCR-ABL do, however, upregulate DNA ligase
III (Sallmyr, Tomkinson et al. 2008). The standard treatment for Philadelphia
chromosome positive CML is imatinib, a small molecule inhibitor of ABL, and it is
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very effective. However, imatinib resistance does occur in these patients and it is
a serious clinical problem. Novel therapeutic approaches are needed to tackle
this problem (Soverini, Martinelli et al. 2005). As noted above, there is evidence
that imatinib-resistant CML cell lines have in increased alt-NHEJ activity. In
accord with this DSB alteration, CML cell lines with elevated levels of PARP1 and
DNA ligase III, are hypersensitive to the combination of a PARP inhibitor,
NU1025, coupled with DNA ligase III inhibitor L67 (Tobin, Robert et al. 2013).

As with the breast cancer research, this Alt-NHEJ phenotype has also
been observed in clinical samples. Bone marrow mononuclear cells from 19 CML
patients that were either sensitive or resistant to Imatinib were analyzed for their
protein expression levels. Just over half (10 out of 19) of these samples
overexpressed both ligase III and PARP1, with a further 21% overexpressing
ligase III but not PARP1. At present, the prognosis for patients that present with
these symptoms is poor. These cells were assayed for their susceptibility to
NU1025 in combination with L67, which produced some striking results. The
patient samples were divided into three groups: sensitive, insensitive, and
partially sensitive. All samples that had normal expression levels of both ligase
III or PARP1 were insensitive to the treatment, as measured by a colony
formation assay. Of those that overexpressed both ligase III and PARP1, 90%
were sensitive to the treatment of both L67 and NU1025 (Tobin, Robert et al.
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2013). This data provides promising pre-clinical evidence for the potential for
DNA ligase inhibitors in the treatment of Alt-NHEJ dependent cancers.

Neuroblastoma

Neuroblastoma is the most common extracranial solid tumor in children,
with the presence of MYCN amplification predicting a very poor prognosis
(Cheng, Hiemstra et al. 1993, Attiyeh, London et al. 2005). Neuroblastomas also
have chromosomal alterations, most frequent of which are 17q gain, and 1p or
11q loss of heterozygosity (Plantaz, Mohapatra et al. 1997, Attiyeh, London et al.
2005). Similar to both breast cancer and CML, neuroblastomas cell lines had
decreased levels of LigIV and Artemis and elevated levels of Alt-NHEJ proteins
PARP1 and LigIII as well as LigI (Newman, Lu et al. 2015). The neuroblastoma
cell lines were hypersensitive to both a PARP inhibitor and L67 as single agents.
These results suggest that increased activity of and dependence upon alt NHEJ
may occur in a wide variety of cancers and that this repair pathway is a promising
therapeutic target in cancers with increased alt NHEJ activity.

Reviewing the Catalog of Ligase Mutations in Cancers

The Catalogue of Somatic Mutations in Cancer (COSMIC)
database maintains information about mutations identified in cancers. Data
retrieved from the COSMIC database shows that, while there have been
mutations in ligase encoding genes found in cancers, they are not very common.
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Each human ligase gene was analyzed in just under 30,000 samples. Mutations
in LIG1, LIG3 and LIG4 were identified at a rate of 0.69%, 0.49% and 0.58%,
respectively. This represents a low rate of mutation, when compared to the rates
of genes one would expect to find mutated in cancers, such as ABL1, which was
mutated in 3.88% of 43,000 tested samples. p53, which is a protein mutated in
many different tumors (Lehman 1974) was found to be mutated in the COSMIC
database 31140 out of 119518 samples tested (26.1%). As for those mutations
that have been catalogued, the DNA binding domain had the greatest percentage
of mutations of the three catalytic domains (DBD, AdD and OBD), but the
difference was less than 10%. In the case of LigI, the plurality of mutations (38%)
were found in the N-terminal domain (Forbes, Beare et al. 2015). Thus, it
appears that expression of DNA ligases is a much better metric by which to
evaluate the potential involvement of DNA ligases as biomarkers, drivers and/or
therapeutic targets in cancer, rather than mutational data.

Introductory Summary

The catalytic region of DNA ligase I encircles and ligates the nicks
between adjacent Okazaki fragments during lagging strand DNA synthesis.
Although there is compelling evidence that interactions with PCNA and RFC are
critical for the specific participation of DNA ligase I in DNA replication, further
studies are needed to delineate the precise molecular mechanisms by which
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these interactions contribute to the coordinated processing and joining of
Okazaki fragments and how these interactions are effected by phosphorylation of
DNA ligase I. The predisposition to cancers exhibited by a mouse model of DNA
ligase I-deficiency highlight the importance of this coordination and regulation in
prevention of genome instability during DNA replication (Harrison, Ketchen et al.
2002). This dissertation has a hybrid structure; chapters two and three are
papers that have been submitted for publication. In accordance with UNM
guidelines, they have only minor edits, mostly for style purposes. All
supplemental figures referenced in these chapters are included here as
expansions on what has been submitted. In my research proposal, I put forward
two specific aims for my graduate work; to identify compounds that improve on
the current generation of ligase inhibitors, and to locate their binding site and
mechanism of action. In the sections below, I describe significant progress
towards achieving both goals
•

Specific Aim 1. Identify determinants of structure, activity and specificity
of DNA ligase inhibitors by characterizing derivatives of the DNA ligase I
inhibitor, L82, and the DNA ligase I/III inhibitor L67. A number of
derivatives have been created for the previously described small molecule
inhibitors of DNA ligase I and DNA ligases I/III. Determine the activity and
selectivity of these chemicals with the goal of identifying more selective
inhibitors for DNA ligase I and DNA ligase III with activity in both
biochemical and cell-based assays.
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o Sub-Aim 1a. The lab currently has a number of compounds,
intermediates between L82 and L67, purchased and synthesized.
Determine if any of these have greater activity and/or specificity for
DNA ligase I over DNA ligase III.
o Sub-Aim 1b. Upon identifying lead candidate(s), characterize them
biochemically in order to determine structure-activity relationships.
If no derivative compounds show improvement over parent
inhibitors, use this information, as well as molecular modeling
results from Specific Aim 2, to either conduct a new computer aided
drug design screen, or synthesize new derivatives for testing.
o Sub-Aim 1c. Characterize the effects of the LigI selective inhibitor
L82 and its derivative L82-G17 in cell culture. Using several cell
types and complementary methods, such as colony assays,
iPOND, and BrdU incorporation, elucidate the effects that L82 and
L82-G17 have on cells. Compare and contrast these effects with
those of L67.

•

Specific Aim 2. Use molecular modeling approaches to predict the
binding site(s) for the current pool of DNA ligase inhibitors and make
specific amino acid substitutions to test these predictions. Identify
residue(s) implicated as playing critical roles in inhibitor binding by
computational approaches. In order to confirm the role of predicted key
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residues, construct mutant versions of the DNA ligases with specific amino
acid substitutions and then characterize their biochemical activity, in
particular sensitivity to inhibition by DNA ligase inhibitors
o Sub-Aim 2a. L82 and L67 have different mechanisms of action
(competitive vs uncompetitive) as well as functional target(s), we
predict that they will bind to different locations within the DNA
binding domain of DNA ligase I. To test this hypothesis, we will
perform molecular modeling assays using the OpenEye suite of
software to dock chemicals known to inhibit DNA ligase I on to the
crystal structure. Cohorts of known DNA ligase inhibitors will predict
the actual binding site.
o Sub-Aim 2b. Evaluate the predicted binding sites by determining
effects of amino acid substitutions within the binding site by both in
silico and biochemical approaches in order to identify residues that
are critical for inhibitor activity. Express mutant versions of the DNA
ligase that are resistant to inhibition in cell lines that lack either
DNA ligase I or DNA ligase III to demonstrate that effects of DNA
ligase inhibitors observed in cell-based assays are due to inhibition
of the target protein rather than off-target effects.
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CHAPTER 2

Characterization of an uncompetitive inhibitor of DNA Ligase I

Submitted for publication in DNA Repair.
Timothy R.L. Howes, Annahita Sallymr, Rhys Brooks, George E. Greco, Darin E.
Jones, Yoshihiro Matsumoto, and Alan E. Tomkinson

Abstract

The integrity of the phosphodiester backbone of DNA is maintained by DNA
ligases. In human cells, there are three genes that encode DNA ligase
polypeptides with distinct but overlapping functions. A series of small molecule
inhibitors of human DNA ligases were identified using a rational structure-based
approach. Three of these inhibitors, L82, a DNA ligase I selective inhibitor, and
L67, an inhibitor of DNA ligases I and III, and L189, an inhibitor of all three human
DNA ligases, have related structures. Here we have performed an initial structureactivity analysis in order to identify determinants of activity and selectivity. Among
the compounds evaluated, we identified L82-G17, a closely related derivative of
L82, that exhibited increased activity against and selectivity for DNA ligase I in
vitro. Notably. L82-G17 is an uncompetitive inhibitor that stabilizes complex
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formation between DNA ligase I and nicked DNA. In accord with this mechanism
of action and published evidence that the trapping of proteins on DNA by inhibitors
correlates with increased cytotoxicity, cells expressing DNA ligase I were more
sensitive to L82-G17 than isogenic LIG1 null cells. Furthermore, the
hypersensitivity of cells lacking nuclear DNA ligase III, which can substitute for
DNA ligase I in DNA replication, to L82-G17, provides further evidence that this
compound inhibits the cellular functions of DNA ligase I. Together our studies
provide a framework for the future design of DNA ligase inhibitors and describe a
novel inhibitor with utility as a probe of the catalytic activity and cellular functions
of DNA ligase I.

Introduction

DNA ligation is required to generate an intact lagging strand during DNA
replication as well as in almost every recombination and DNA repair event. In
human cells, this reaction is carried out by the DNA ligases encoded by the three
human LIG genes (Ellenberger and Tomkinson 2008). Genetic analysis has
revealed that there is considerable functional overlap among the DNA ligases
encoded by the three LIG genes in nuclear DNA transactions (Frosina, Fortini et
al. 1996, Audebert, Salles et al. 2004, Wang, Rosidi et al. 2005, Moser, Kool et
al. 2007, Liang, Deng et al. 2008, Simsek, Brunet et al. 2011, Arakawa, Bednar
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et al. 2012, Le Chalony, Hoffschir et al. 2012, Han, Masani et al. 2014, Oh,
Harvey et al. 2014) whereas only the DNA ligase encoded by the LIG3 gene,
DNA ligase III (LigIII, functions in mitochondrial DNA replication and repair
(Lakshmipathy and Campbell 1999, Gao, Katyal et al. 2011, Simsek, Furda et al.
2011, Sallmyr, Matsumoto et al. 2016).

The steady state levels of DNA ligase I (LigI) are frequently elevated in
cancer cell line and tumor samples (Sun, Urrabaz et al. 2001, Chen, Zhong et al.
2008). This presumably reflects the hyperproliferative activity of cancer cells
since LigI is the predominant ligase involved in DNA replication (Lasko,
Tomkinson et al. 1990, Barnes, Tomkinson et al. 1992, Levin, McKenna et al.
2000). Unexpectedly, many cancer cell lines exhibit both increased steady state
levels of LigIII and reduced steady state levels of DNA ligase IV (LigIV), with
these reciprocal changes indicative of alterations in the relative contribution of
different DNA repair pathways between non-malignant and cancer cells (Chen,
Zhong et al. 2008, Sallmyr, Tomkinson et al. 2008, Tobin, Robert et al. 2012,
Tobin, Robert et al. 2013, Newman, Lu et al. 2015). The dysregulation of DNA
ligases in cancer cells together with the involvement of these enzymes in the
repair of DNA damage caused by agents used in cancer chemotherapy and
radiation therapy suggests that LigI inhibitors may have utility as cancer
therapeutics.
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Figure 3. Chemical Structures of DNA ligase inhibitors identified by
computer aided drug design
Structures and selectivity of three previously described small-molecule inhibitors
of human DNA ligases, L67, L82 and L189, are shown.

A set of small molecule LigI inhibitors were identified through an in silico
structure-based screen, using the atomic resolution structure of LigI complexed
with nicked DNA (Chen, Zhong et al. 2008). This screen yielded inhibitors that
were selective for LigI (L82), inhibited both LigI and LigIII (L67) and inhibited all
three human DNA ligases (L189) (Fig. 3). As expected, subtoxic levels of L67
and L82 enhanced the cytotoxicity of DNA damaging agents in cancer cell lines
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(Chen, Zhong et al. 2008). Surprisingly, under similar conditions, non-malignant
cell lines were not sensitized to DNA damage by the DNA ligase inhibitors,
suggesting that there are alterations in genome maintenance pathways between
non-malignant and cancer cells (Chen, Zhong et al. 2008). Further studies
revealed that the repair of DNA double-strand breaks is abnormal in cancer cells
with elevated levels of LigIII and PARP1 and that these cells are hypersensitive
to inhibitors that target LigIII and PARP1 (Tobin, Robert et al. 2012, Tobin,
Robert et al. 2013, Newman, Lu et al. 2015).

The DNA ligase inhibitors L82, L67 and L189 share some similarities in
that they are each composed of two 6-member aromatic rings separated by
different length linkers (Fig. 3). Here we have examined a series of related
compounds in an attempt to identify determinants of activity and selectivity for
LigI and LigIII. One of the compounds analyzed, L82-G17, is a selective,
uncompetitive inhibitor of LigI. Furthermore, the activity of this compound in cell
culture assays with genetically-defined cell lines indicates that it inhibits LigI
function in cells.
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Results

Biochemical activity of L82 derivatives

To gain insights into determinants of activity and selectivity, we either
synthesized (L82-GXX) or purchased (L82-XX) compounds (Fig. 4C) whose
structures were related to L82 but also exhibited similarities with the LigI/III
inhibitor L67 and the inhibitor of all three human DNA ligases L189 (Fig. 3). In
initial studies, we examined the effects of the L82 derivatives on LigI, LigIII and
T4 DNA ligase activity. The DNA ligase IV/XRCC4 complex (LigIV/XRCC4) was
not included in these assays as the purified enzyme, unlike LigI, LigIII and T4
DNA ligase, acts as a single turnover enzyme (Riballo, Woodbine et al. 2009,
Chen and Tomkinson 2011). Any compounds that inhibited T4 DNA ligase, which
lacks the DNA binding domain targeted in the structure-based screen (Chen,
Zhong et al. 2008), were presumed to be non-specific inhibitors and excluded.
The activities of the remaining compounds were compared with the previously
described DNA ligase inhibitors, L82, L67 and L189 (Chen, Zhong et al. 2008) at
50 µM (Fig. 4A and 4B). Among the 10 compounds that inhibited LigI by at least
40%, 5 compounds preferentially inhibited LigI, 2 compounds preferentially
inhibited LigIII and 3 compounds had similar activity against both LigI and LigIII
(Fig. 4B and 4C). Among the 5 preferential inhibitors of LigI, two compounds,
L82-30 and L82-G17 exhibited increased selectivity for LigI compared with L82
(Fig. 4B).
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The linkers between the two aromatic rings of all the DNA ligase inhibitors
can be grouped into three major types, vinyl, arylhydrazone, and acylhydrazone,
linking the rings with 2, 3, and 4 atoms, respectively. None of the LigI selective
inhibitors has a vinyl linker. In addition, all the LigI selective inhibitors except for
L82-22 have a pyridazine ring whereas the LigI/LigIII and LigIII inhibitors do not.
Comparing geometric shape coefficients, a value that represents a molecule’s
potential size based on the connections between atoms, the mean value for LigI
selective inhibitors (7.4) was significantly different (p < 0.05) than that of LigI/III
inhibitors (9.5). The mean geometric shape coefficient of LigI selective inhibitors
was also significantly different than that of compounds that do not inhibit either
LigI or LigIII. A further point of differentiation between LigI selective and LigI/LigIII
inhibitors is their calculated partition coefficient (LogP). The calculated LogP is
significantly lower for LigI selective inhibitors than inhibitors of both LigI and
LigIII, 2.53 and 4.6 respectively (p < 0.01).

L82-G17 is an uncompetitive inhibitor of LigI

We chose to focus on characterizing L82-G17 because of its higher
potency and increased selectivity. L82-G17 is more related to L82 than L67 with
Tanimoto similarity scores of 78% and 32%, respectively, calculated using the
Maximum Common Substructure method. The repositioning of a hydroxyl group
on the non-pyridazine ring from para to meta, and the removal of a nitro group,
appears to increase the selectivity of L82-G17 for LigI over LigIII. As was
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Figure 4. Activity and structures of compounds related to L67, L82 and
L189
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Figure 4. Activity and structures of compounds related to L67, L82 and
L189.
The activity of L67, L82, L189 and L82 derivatives at 50 µM against LigI
(0.625 nM) and LigIII (1.75 nM) were measured in assays with the
radiolabeled DNA substrate as described in Materials and Methods. (A) L67,
L82 and L189. (B) L82 derivatives. Results are shown graphically with
inhibition expressed as a percentage of the values in assays with DMSO
alone. Data shown is the result of at least three independent experiments. (C)
Chemical structures of L82 derivatives that are grouped based on their
selectivity for LigI (inhibit LigI more than LigIII by at least 20% and inhibit LigI
by at least 40%), selective for LigIII (inhibit LigIII more than LigI by at least
20% and inhibit LigIII by at least 40%), have similar activity against LigI and
LigIII, or have less than 40% activity against both enzymes (ungrouped).
observed with L82 (Chen, Zhong et al. 2008), L82-G17 did not inhibit LigIV at
concentrations up to 200 M (data not shown).

Among the LigI inhibitors identified by computer-aided drug design, L82
was unique in that it appeared to act as an uncompetitive rather than a
competitive inhibitor (Chen, Zhong et al. 2008). This prompted us to examine the
effects of L82 (Fig. 5A) and L82-G17 (Fig. 5B) on the kinetics of ligation by LigI.
Under these reaction conditions, the Vmax and Km values for DNA ligase were 0.9
pmol ligations per min and 1.4 M, respectively. Notably, the addition of L82
increased Km and decreased Vmax, whereas L82-G17 reduced both Km and Vmax.
The Lineweaver-Burk plots obtained with L82 (Fig. 5C) indicate that this
compound is in fact a mixed inhibitor that acts by both uncompetitive and
competitive mechanisms. In contrast, the Lineweaver-Burk plots obtained with
L82-G17 indicate that this compound is an uncompetitive inhibitor (Fig. 5D).
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Figure 5. L82-G17 is an uncompetitive inhibitor
Michaelis-Menten saturation curve of at least three independent fluorescencebased ligation assays (Materials and Methods) depicting graphically the effect of
increasing concentration of inhibitor on the affinity for substrate (µM) and velocity
of the reaction (pmol/min) for compounds L82 (A) and L82-G17 (B). LineweaverBurk plot representation of the same data for compounds L82 (C) and L82-G17
(D), with standard error of mean and extrapolated trendline, are shown
(uninhibited solid line, long dashes 20 µM, and short dashes 200 µM).

Electrophoretic mobility shift assays (EMSAs) and pulldown assays with a
linear duplex containing a single non-ligatable nick were used to confirm the
uncompetitive mechanism of L82 and L82-G17. As expected, L82 and, to a
greater extent, L82-G17, increased the amount of LigI-DNA complex whereas the
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Figure 6. L82 and L82-G17 increase binding to nicked DNA whereas L67
decreases binding
(A) A representative gel showing the effect of the inhibitors, L67, L82 and L82G17, at 100 µM and DMSO alone on DNA-protein complexes formed by LigI with
nicked DNA. The position of the DNA substrate (DNA alone) and the LigI-DNA
complex (DNA + Ligase I) are shown. LigI bound (upper band) and unbound
(lower band) to radiolabeled DNA substrate. (B) Results of at least three
independent EMSA assays are shown graphically. The effect of the inhibitors,
L82 (closed squares), L82-G17 (closed triangles) and L67 (closed circles) on
DNA-protein complex formation by LigI expressed as the ratio of bound and
unbound DNA relative to uninhibited LigI. (C) The effect of L82 and L82-G17 on
the amount of labeled LigI retained by streptavidin beads liganded by biotinylated
nicked DNA. Results of three independent assays are shown graphically and
expressed as a percentage LigI retained in assays with DMSO alone. (D) The
effect of L67 and L82-G17 on the amount of labeled LigI and LigIII retained by
streptavidin beads liganded by biotinylated nicked DNA. Results of three
independent assays are shown graphically and expressed as a percentage
LigI/LigIII retained compared with assays with DMSO alone.

competitive inhbitor L67 reduced the amount of LigI-DNA complex (Fig. 6A and
B). In pulldown assays with streptavidin beads liganded by a biotinylated linear
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duplex containing a single non-ligatable nick, both L82 and L82-G17 increased
the amount of labeled LigI retained by the beads in a concentration-dependent
manner (Fig. 6C). In similar assays, 14% and 3.6% of LigI was retained by beads
liganded by intact double-stranded DNA, and single-stranded DNA, respectively
(data not shown) compared with the beads liganded by DNA with a single nonligatable nick. Taken together these results demonstrate L82-G17 is an
uncompetive inhibitor of LigI. To confirm the selectivity of L82-G17 for LigI, we
performed pull down assays with both LigI and LigIII. As expected, the LigI/III
competitive inhibitor L67 reduced the binding of both LigI and LigIII to the beads.
In contrast, L82-G17 increased the retention of LigI by the beads but had vey
little effect on LigIII binding (Fig. 6D).

Effects of L82-G17 on replicative DNA synthesis and cell proliferation

Since LigI is the DNA ligase predominantly responsible for joining Okazaki
fragments during replicative DNA synthesis (Barnes, Tomkinson et al. 1992,
Levin, McKenna et al. 2000, Bentley, Harrison et al. 2002), we examined the
effect of L82-G17 and L82 on the incorporation of bromodeoxyuridine (BrdU) by
an asynchronously proliferating popoulation of HeLa cells. While both L82 and
L82-G17 reduced BrdU incorporation, their effects were modest compared with
the LigI/III inhbitor L67 (Fig. 7A). This is consistent with studies showing that LigI
is not essential for mammalian DNA replication becase of the ability of LigIII to
act as a back-up (Bentley, Selfridge et al. 1996, Bentley, Harrison et al. 2002, Le

50

Figure 7. Effects of ligase inhibitors DNA synthesis, cell viability and DNA
damage
The effects of L67, (closed circles) L82, (closed squares) or L82-G17 (closed
triangles) on BrdU incorporation, cell viability and formation of H2AX foci were
determined as described in Materials and Methods. (A) Asynchronous HeLa
cells were treated with the ligase inhibitors for 4 hours and were then assayed
for BrdU incorporation. Results of three independent assays are shown
graphically. (B) HeLa cells were incubated with the inhibitors for 5 days prior to
the determination of cell viability using the MTT assay. Results of three
independent assays are shown graphically. Data points at 20 and 30 µM are
significant at p < 0.005. (C) HeLa cells were incubated with the ligase inhibitors
for 4 hours prior to the detection of γH2AX foci by immunocytochemistry. Cells
that contained at least 5 foci were counted as γH2AX positive. At least 100 cells
counted per data point. The results of 3 independent assays shown.

Chalony, Hoffschir et al. 2012, Han, Masani et al. 2014). Since the DNA
synthesis assay involved a relatively short incubation with the DNA ligase
inhibitors, we examined their impact on cell proliferation over a 72 h time period
using the MTT assay that quantitates the activity of NAD(P)H-dependent cellular
oxidoreductase enzymes, an indicator of metabolic activity that correlates with
the number of viable cells. L82-G17 was a more effective inhibitor of proliferation,
reducing cell number by about 70% at 20 M compared with a 30% reduction
with 20 M L82. Similar results were obtained with L82 and L82-G17 using a
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CYQUANT assay that measures genomic DNA, another indicator of cell number
(Jones, Gray et al. 2001) (data not shown).

Since L82 and L82-G17 had more severe effects on proliferation (Fig. 7B)
than replicative DNA synthesis (Fig. 7A), we asked whether these compounds
induced DNA damage that could activate cell cycle checkpoints, thereby
reducing cell proliferation. Acute exposure to either L82 or L82-G17 for 4h,
resulted in a concentration-dependent increase in formation of γH2AX foci, an
indicator of DNA double-strand breaks (DSB)s (Fig. 7C) (Bonner, Redon et al.
2008). In accord with the cell proliferation (Fig. 7B) and DNA synthesis (Fig. 7A)
assays, L67 was more effective at inducing γH2AX foci than either L82 or L82G17 (Fig. 7C).

Cells lacking LigI are less suseptible to L82 and L82-G17

While the effects of L82-G17 and L82 on proliferation, BrdU incorporation
and DNA damage are consistent with these inhibitors impacting DNA replication
by inhibiting LigI, it is possible that they may be due to off-target effects. This
prompted us to compare the effects of L82 and L82-G17 on the parental and LigI
null derivatives of the mouse B cell line, CH12F3 (Fig. 8A) (Nakamura, Kondo et
al. 1996, Han, Masani et al. 2014). Notably, both L82 and L82-G17 had a greater
effect on the proliferation (Fig. 8B) and the survival (Fig. 8C and 8D) of the
parental CH12F3 cells compared with the LigI null derivative, suggesting that, in
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Figure 8. Cells lacking LigI are more sensitive to L82 and L82-G17
(A) LigI, LigIII and -actin proteins were detected in extracts of CH12F3 WT and
CH12F3  cells by immunoblotting. (B) Effect of L82 (square) and L82-G17
(triangle) on the proliferation of CH12F3 WT (filled symbols) and CH12F3 
(empty symbols) cells was measured by the CyQUANT assay as described in
Materials and Methods. Effect of L82 (C) and L82-G17 (D), colony formation by
CH12F3 WT and CH12F3  cells. Data shown graphically are the mean ±SEM
of three independent experiments and are expressed as a percentage of the
values for the untreated cells. * p < 0.05 and *** p < 0.001 using the unpaired
two-tailed Student test.

the presence of LigI, these uncompetitive inhibitors cause DNA-protein adducts
by trapping LigI on chromosomal DNA. Additional data is provided in Figure S2.
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The absence of nuclear LigIII increases sensitivity to L82 and L82-G17.

Cells with both nuclear LigI and LigIII should be more resistant to a
selective LigI inhibitor compared with cells with only nuclear LigI because of the
functional redundancy between LigI and LigIII in DNA replication. To confirm
this, we examined the effects of L82 and L82-G17 on the proliferation of a
derivative of the human colorectal cancer cell line HCT116 that lacks nuclear
LigIIIand its parental cell line (Fig. 9A). The absence of nuclear LigIII
markedly increased the inhibitory activity of L82-G17 (Fig. 9C) on cell
proliferation whereas L82 had a smaller effect (Fig. 9B).Taken together, our
results indicate that the activities of L82 and, in particular, L82-G17 in cell culture
assays are due primarily to inhibition of LigI.

Discussion

There is emerging interest in the use of DNA repair inhibitors to exploit
either cancer cell-specific alterations in or increased dependence upon genome
maintenance pathways (Jackson and Helleday 2016). The abnormal expression
of DNA ligases in cancer cell lines and samples from cancer patients suggest
that DNA ligase inhibitors may have utility as anti-cancer agents either alone or in
combination with DNA damaging agents (Sun, Urrabaz et al. 2001, Chen, Zhong
et al. 2008, Tobin, Robert et al. 2012, Tobin, Robert et al. 2013, Newman, Lu et
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Figure 9. Cells lacking nuclear LigIII
G17

are more sensitive to L82 and L82-

(A) Fluorescent image of HCT116 Flox-/- expressing YFP tagged mito LigIII
cells. Scale bars, 10 m (left panel). Immunoblots with extracts of HCT116,
HCT116 Flox+/- and HCT116 Flox-/- Mito Ligase 3using antibodies against
GFP, LigIII, LigI and -actin. The positions of YFP-fusion protein (GFP), mito
LigIII fused to GFP (Mito Ligase III) and endogenous LigIII (Ligase III), LigI
(Ligase I) and -actin are indicated (middle panel). Wild type and Floxed LIG3
alleles and the integrated cDNA encoding YFP-tagged Mito LigIII were detected
in genomic DNA from HCT116, HCT116 Flox+/- and HCT116 Flox-/- Mito Ligase
IIIby PCR as described in Materials and Methods (right panel). Proliferation of
HCT116 cells (circles) and a derivative lacking nuclear LigIII (diamonds)
incubated with (B) L82 or (C) L82-G17 for 5 days was measured by CyQUANT as
described in Materials and Methods. Results of three independent assays are
shown graphically.
al. 2015). Following the determination of the atomic resolution structure of LigI
complexed with nicked DNA, small molecule inhibitors with differing activities
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against three human DNA ligases were identified by computer-aided drug design
(Chen, Zhong et al. 2008, Zhong, Chen et al. 2008). The DNA ligase inhibitors
were separated into three groups, LigI selective, LigI/III selective and inhibitors of
all three human DNA ligases with L82, L67 and L189, respectively, serving as the
representative compound for each of the groups. Here we examined the activity
of compounds that are related to L82, L67 and L189 to gain insights into
determinants of activity and selectivity. Each of the initial compounds, which
differed in terms of their inhibitory activity against the three human DNA ligases,
contained two aromatic rings but had linkers that differed in length and chemical
composition (Fig. 3). Tested compounds were divided into groups by structure,
vinyl (Fig. 8A), arylhydrazone (Fig. 10B), and acylhydrazone (Fig, 10C). The
majority of LigI selective inhibitors had a 3-atom arylhydrazone linker (Fig. 10B).
The greatest difference between active and inactive arylhydrazone class
inhibitors occurs at the meta positions (8 and 10, Fig. 10), which must contain at
least one polar group, such as the phenol in L82-G17. This observation also
holds true for LigI selective acylhydrazone class inhibitors L82-21 and L82-22,
which have either a nitro or a hydroxyl group at their position 10. Arylhydrazone
linked inhibitors have the greatest potential for future development of LigI specific
inhibitors, as no chemical in this category has activity against LigIII. However, the
presence of the hydrazone linkage may hinder drug development with this
scaffold as this functional group has been shown to be promiscuous and a metal

56

Figure 10. Grouping of active L82 derivatives based their chemical
similarity
All L82 derivatives in this study fall into three structural groups: (A) vinyl linked,
(B) hydrazide linked, (C) and hydrazone linked inhibitors. The members of each
group are identified here. Compounds that inhibit either LigI or LigIII are shown in
bold text, LigI specific inhibitors are also underlined.
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scavenger which can lead to toxicity issues (Charkoudian, Pham et al. 2006,
Baell and Holloway 2010, Peng, Tang et al. 2011).

Among the compounds related to L82, L67 and L189, we identified one
compound, L82-G17 that exhibited increased activity against and increased
selectivity for LigI compared with L82. Notably, it has the lowest molecular weight
of all hydrazine inhibitors with activity against LigI, suggesting that it may
represent the minimal requirements for this type of inhibitor. Further analysis
revealed that L82-G17 is an uncompetitive inhibitor that stabilizes the LigI-nicked
DNA reaction intermediate whereas L82 appears to act by both competitive and
uncompetitive mechanisms. Thus, L82-G17 acts by the same mechanism as
topoisomerase inhibitors, such as camptothecin, and a subset of PARP inhibitors
that trap topo I-DNA and PARP1-DNA complexes, respectively (Staker, Hjerrild
et al. 2002, Pommier, O'Connor et al. 2016). The increased cytotoxicity of L82G17 compared with L82 is consistent with the studies showing that PARP
inhibitors that trap PARP1-DNA complexes are more cytotoxic than PARP
inhibitors that do not (Murai, Huang et al. 2012, Pommier, O'Connor et al. 2016).
It is presumed that DNA-protein complexes, even when non-covalent, cause
problems because of collisions with either the DNA replication or transcription
machinery. In contrast to the trapped DNA-protein complexes formed by
topoisomerases and PARPs, the replication machinery is unlikely to encounter
trapped LigI-DNA protein complexes as these will predominantly formed behind
the fork on the lagging strand.

58

Since the initial identification of DNA ligase inhibitors by a structure-based
approach (Chen, Zhong et al. 2008, Zhong, Chen et al. 2008), there have been
several reports describing LigI inhibitors using computer modeling and
derivatives of the original DNA ligase inhibitors (Krishna, Singh et al. 2014,
Shameem, Kumar et al. 2015, Pandey, Kumar et al. 2017). While these studies
have shown that the inhibitors have activity against LigI in vitro, their affinity and
selectivity appears to be less than L82-G17. Furthermore, there is no definitive
evidence that these inhibitors target LigI in cells. Here we have shown that LIG1
null cells are more resistant to L82-G17, presumably because there is no
formation of trapped LigI-DNA complexes. Furthermore, cells that lack nuclear
LigIII are more sensitive to L82-G17 as they lack a back-up activity for DNA
replication.

The elevated levels of LigI in cancer cells (Sun, Urrabaz et al. 2001, Chen,
Zhong et al. 2008) and the apparent viability of mammalian cells that lack LigI
(Bentley, Selfridge et al. 1996, Bentley, Harrison et al. 2002, Han, Masani et al.
2014) suggest that LigI selective inhibitors may preferentially target cancer cells
because of their high proliferation rate. Toxicity in normal cells is likely be limited
because of the ability of LigIII to substitute for LigI in DNA replication and repair
(Arakawa, Bednar et al. 2012, Le Chalony, Hoffschir et al. 2012) In the structureactivity studies described here, we have identified and characterized a novel
uncompetitive inhibitor of LigI that selectively targets LigI both in in vitro and in

59

cells. Further work to develop improved uncompetitive inhibitors would be
enhanced by the determination of atomic resolution structures of inhibitor-bound
LigI-DNA complexes (Pascal, O'Brien et al. 2004). Alternatively, the predicted
binding site for the LigI inhibitors could be validated using site-directed
mutagenesis to generate versions of LigI that retain wild type catalytic activity but
are resistant to the inhibitors.

Materials & Methods

Chemicals

L67 (IUPAC: 2-[(3,5-dibromo-4-methylphenyl)amino]-N'-[(2-hydroxy-5nitrophenyl)methylidene]acetohydrazide), L82 (IUPAC: 4-chloro-5-{2-[(4-hydroxy3-nitrophenyl)methylidene]hydrazin-1-yl-2,3-dihydropyridazin-3-one, and L189 (6amino-5-[(phenylmethylidene)amino]-2-sulfanylpyrimidin-4-ol) were originally
purchased from ChemDiv and Specs. Milligram quantities of each of the
derivatives reported herein were also purchased from ChemDiv, Specs, or
ChemBridge.
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Large scale synthesis of L82-G17 (4-chloro-5-{2-[(3hydroxyphenyl)methylidene]hydrazin-1-yl}-2,3-dihydropyridazin-3-one)

4,5-Dichloropyridazin-3(2H)one (660 mg, 4.0 mmol, 1.0 equiv) was
dissolved in methanol (7 mL). Hydrazine monohydrate (380 mg, 7.6 mmol, 1.9
equiv) was dissolved separately in methanol (4 mL). Both solutions were
combined and the reaction was heated at reflux for 1.5 hours. Additional
methanol (3 mL) was added during heating, as the precipitate of product inhibited
stirring. The reaction was cooled and the product was separated from the
supernatant through vacuum filtration and dried overnight, yielding 5-chloro-4hydrazidopyridazin-3(2H)one as a light yellow-brown powder (504 mg, 3.13
mmol, 78%). 1H NMR (DMSO, 400 MHz) δ 12.46 (s, 1H, N-H), 8.07 (s, 1H, aryl),
7.96 (s, 1H, N-H), 4.57 (s, 2H, NH2). This intermediate (100 mg, 0.62 mmol, 1.0
equiv) was dissolved into ethanol (1000 mL) with heat and 3hydroxybenzaldehyde (91 mg, 0.75 mmol, 1.2 equiv) was added as a solid. The
reaction mixture was heated under reflux overnight, then concentrated to 5 mL to
precipitate a light brown solid. The product was collected, washed with ethanol,
and dried under vacuum, yielding 78 mg, 0.295 mmol, 48%). 1H NMR (DMSO,
400 MHz) δ 12.86 (s, 1H, N-H), 10.74 (s, 1H, N-H), 9.59 (s, 1H, O-H), 8.32 (s,
1H, imine C-H), 8.31 (s, 1H, Ar) 7.23 (t, 1H, Ar), 7.12 (s, 1H, Ar), 7.11 (d, 1H, Ar),
6.80 (d, 1H, Ar).
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MarvinSketch v.14.9.8.0 (ChemAxon (http://www.chemaxon.com)) was
used for drawing chemical structures. Tanimoto similarity scores were calculated
using the Maximum Common Substructure algorithm in online tool ChemMine
(Backman, Cao et al. 2011).

Proteins

After expression in E. coli BL21(DE3) cells, N-terminally poly(histidine)tagged wild type human LigI was purified by HisTrap and HiTrap Q (GE
Healthcare Life Sciences) column chromatography as described (Peng, Liao et
al. 2016). In addition, a version of LigI with C-terminal poly(histidine), FLAG tags
and PKA site was expressed in Rosetta2 cells and then purified by HisTrap HP
and HiTrap Q column (GE Healthcare Life Sciences) column chromatography.
Purified LigI fractions were pooled, concentrated using a 50 kDa MWCO
centrifugal filter (EMD Millipore), and then stored at -80°C LigIII and the
LigIV/XRCC4 complex were purified from E. coli and insect cells, respectively as
described previously (Chen, Pascal et al. 2006, Chen, Ballin et al. 2009).

DNA Ligation Assays

Nick joining was measured using radioactive- and fluorescence-based
assays (Chen, Pascal et al. 2006, Chen, Ballin et al. 2009). The concentrations
of oligonucleotides (Integrated DNA Technologies) DNA were measured using
absorbance at 260 nm. In radioactive assays, the olignucleotide (5’
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CAAATCTCGAGATCACAGCAACTAGACCA) was 5’ end labeled with
polynucleotide kinase and -32P-ATP. After removing excess ATP using a P-30
polyacrylamide spin column (Bio-Rad), the labeled oligonucleotide was annealed
with a longer complementary template oligonucleotide (5’
CCATCTTAAGGAGTGCAGTAGAAGTCCAGATCAACGACACTAGAGCTCTAA
ACGCAAGGCAACTGCATGGACGAACACTCGCGAGTGTTAATG) and another
oligonucleotide (5’GTAATTGTGAGCGCTCACAAGCAGGTACGTCAACGGAACG) that was also
complementary to the template oligonucleotide, to generate a linear duplex with a
single radiolabeled ligatable nick. DNA ligases and putative inhibitors were
preincubated for 10 minutes at room temperature prior to the addition of the
labeled DNA substrate (500 fmol) and incubation at 25°C for 30 minutes in a final
volume of 20 l containing 25 mM Tris-HCl pH 7.5, 12.5 mM NaCl, 6 mM MgCl2,
0.4 mM ATP, 0.25 mg/mL BSA, 2.5% glycerol, 0.5 mM DTT, and 0.5% dimethyl
sulfoxide (DMSO). Reactions were stopped by placing reaction tubes on ice
followed by the addition of formamide dye. After heating at 95°C for 5 minutes,
labeled oligonucleotides were separated by electrophoresis through a 15%
polyacrylamide-urea gel and then quantitated by phosphorimager analysis on a
Typhoon FLA 7000, using a 650nm laser (software version 1.2). Images were
analyzed using the Fuji Film MultiGauge software (version 3.0). The substrate
oligos were purified in house (Fig. S3).
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In the fluorescence-based ligation assay (Chen, Pascal et al. 2006, Chen,
Ballin et al. 2009), purified LigI (500 fmol) was incubated in the presence or
absence of either L82 or L82-G17 with fluorescent nicked DNA (1 pmol) for 5 min
in a final volume of 20 l containing 60 mM Tris–HCl pH 7.4, 50mM NaCl, 10 mM
MgCl2, 5 mM DTT, 1 mM ATP, 50 μg/ml BSA, and 4% DMSO) at 25 °C.
Following incubation, reactions were further diluted to 200 μL with a 30-fold molar
excess of an unlabeled oligonucleotide (5’TAGGAGGGCTTTCCTCCTCACGACCGTCAAACGACGGTCA) identical in
sequence to the ligated strand in 10 mM Tris–HCl pH 7.4, 50 mM KCl, 1 mM
EDTA and 5 mM MgCl2 for 5 min, and then heated to 95 °C for 5 min. After
cooling to 4 °C at a rate of 2 °C/min, fluorescence at 519 nm (excitation at
495 nm) was measured immediately using the Synergy H4 microplate reader
(BioTek). Data, including Michaelis-Menten and Lineweaver-Burk equations and
kinetic values, were calculated through GraphPad Prism software and graphed in
Microsoft Excel.

DNA binding Assays

For electrophoretic mobility shift assays, a radiolabeled 73 bp linear
duplex with a single nick was generated as above except that there was a
dideoxycytosine residue at the 3’ terminus of the nick (Pascal, O'Brien et al.
2004, Chen, Zhong et al. 2008). Putative inhibitors, 1500 fmol DNA ligase and
the 500 fmol nicked substrate were incubated in 50 mM Tris-HCl pH 7.5, 15 mM
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NaCl, 1 mM DTT, 0.2 mM ATP, 0.005 mg/mL BSA, 5 mM MgCl2, 8.75% glycerol
and 0.5% DMSO for 30 min. After electrophoresis through a 5% non-denaturing
polyacrylamide gel using 0.5x TBE pH 8.3 as running buffer, labeled
oligonucleotides were detected by phosphorimager and imaged as described
above.

For DNA binding assays using magnetic beads, a non-radioactively
labeled version of the DNA substrate used in the ligation assay was constructed
with non-phosphorylated versions of the same three oligonucleotides except that
a biotin molecule was attached to the 5’ end of long template oligo. Purified LigI
was 32P-labeled by protein kinase A (New England Biolabs). Labeled LigI (1
pmol) and the biotinylated DNA substrate (1 pmol) bound to streptavidin
magnetic beads were mixed in 20 mM HEPES-KOH pH 7.5, 20 mM NaCl, 10 mM
MgCl2, 5 g/mL BSA, and 4% glycerol in a final reaction volume of 40 µL prior to
incubation at 25°C for 30 minutes prior to capture of the beads using a magnetic
tube rack. The beads were washed 3-times with a 20 mM HEPES-KOH pH 7.5,
100 mM NaCl, and 10 mM MgCl2 before to heating at 95°C for 5 minutes with
SDS sample buffer. Eluates from the beads were electrophoresed through a 10%
denaturing polyacrylamide gel. Labeled LigI was detected by phosphorimager
analysis and imaged as described above.
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Cell Lines

Human cervical (HeLa) and colorectal (HCT116) cancer cell lines were
acquired from the ATCC (Manassas, VA) and grown in the recommended media.
The mouse B cell lines CH12F3 Lig1 WT and CH12F3 Lig1  (Nakamura,
Kondo et al. 1996, Han, Masani et al. 2014) were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin and 55 M of -mercaptoethanol. HCT116 cells were
maintained in McCoy’s 5A supplemented with 10% FBS and 1% Pen/Strep.
HCT116 LIG3Flox+/- cells containing a conditional LIG3 allele and a deletion
allele (Oh, Harvey et al. 2014) were further engineered to express
mitochondrially-targeted human LigIII. A full length human LigIII cDNA that
encodes the mitochondrial leader sequence was mutated so that the internal
ATG start codon for nuclear LigIII was altered to ATC and then fused in-frame
to an EYFP gene in the pCAG-YFP-neo plasmid to generate pCAG-MitoLigIII
alpha-YFP-neo. After verification by structure DNA sequencing, this plasmid was
transfected into HCT116Flox+/- cells and YFP-positive cells were selected by flow
cytometry. To delete the remaining conditional LIG3 allele, cells were infected
with an adenovirus type 5 (dE1/E3) virus encoding the Cre recombinase, (AdCMV-Cre #1045, Vector Biolabs). After 24 h, cells were washed and then
cultured in fresh medium containing 0.5 mg/ml G418. Single cells were isolated
in 96-well plates using an SY3200 cell sorter. Extracts of G418-resistant YFP-
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positive clones were probed by immunoblotting with antibodies to human LigIII
(GeneTEX #103172), LigI (Peng, Liao et al. 2012) and GFP (Santa Cruz #8334).
The Lig3-/- genotype was confirmed using primers Lig3 Exon 5 F1: 5'-AAA GCA
ACC CTC CTG TCT TCT CCT GCA AGT-3' and Lig3 Exon 5 R1: 5'-TGG TAC
CAG GGA TAG AGT CAC GGA CAA ACC AA-3'.

Bromodeoxyuridine (BrdU) incorporation

Asynchronous populations of HeLa cells were incubated with the DNA
ligase inhibitors for 4 h prior to pulse labeling with BrdU (10 M) for 45 minutes.
Immunofluorescent staining of cells was performed using a BD BrdU flow Kit (BD
Pharmingen) according to the manufacturer’s instructions and then quantitated
by flow cytometry using an LSR Fortessa in the UNMCCC Shared Flow
Cytometry and High Throughput Screening Resource. Total cellular DNA was
stained with 7-AAD prior to analysis by flow cytometry. Data was analyzed using
FlowJo (software version 10.1).

Cell Viability, Proliferation and survival assays

Cells were cultured in 96-well plates with either ligase inhibitors, or DMSO
alone, for 5 days at 37°C. Cell viability was measured using the MTT assay, in
which a tetrazolium dye, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, is metabolized into (E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3diphenylformazan in the mitochondria, resulting in a colour change from yellow to
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purple. After incubation with the MTT reagent (Promega) for one hour at 37°C
per the manufacturer’s instructions, absorbance at 570 nm was measured using
a PerkinElmer Victor 3V1420 Multilabel Counter. Cell viability is expressed as a
percentage of the value obtained with DMSO-treated cells.

To quantitate genomic DNA as a measure of cell proliferation, cells were
plated at density of 2000 per well in a 96-well in the presence or absence of L82
and L82-G17 and cultured for 72 h. After washing with 1 x PBS, the CyQUANT
NF reagent (CyQUANT NF Cell Proliferation Assay Kit, Invitrogen) was added
and incubation continued for 1h at 37oC according to the manufacturer’s
instructions. Fluorescence intensities of triplicate samples were measured with a
fluorescence microplate reader using excitation at 485 +/- 10nm and
fluorescence detection at 530 +/- 15 nm. Cell number is expressed as a
percentage of the value obtained with DMSO-treated cells.

Colony forming assays with CH12F3 Lig1 WT and CH12F3 Lig1 cells
were performed in methylcellulose-based media (Cat #HSC001 R&D Systems),
which was diluted 1:3 with cell medium (RPMI Medium 1640, 10% FBS, 1%
penicillin/streptomycin and 55 M of -mercaptoethanol) for approximately 30
minutes without disturbance. Cells were counted in order to have 300 cells per
well of a 6-well plate. L82 and L82-G17 were added to cell suspensions and
vortexed briefly, prior to the addition of 3 mL of methylcellulose-based medium
and plating. After incubation for 10 days at 37°C in 5% CO2, colonies were
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stained overnight with 1 mL of 1 mg/mL iodonitrotetrazolium chloride per well.
Colonies were counted using ImageJ Cell Counter.
Formation of H2AX
To detect H2AX foci by immunocytochemistry, HeLa cells were grown on
coverslips as described above in 12-well plates. Each well was seeded with 5000
cells that were allowed to adhere for at least 8 hours prior to incubation with
inhibitors or DMSO alone for 4 hours. Cells were then incubated with anti-γH2AX
FITC-conjugated antibodies using a kit purchased from BD Pharmingen and 4',6Diamidino-2-Phenylindole (DAPI) to stain nuclei. After mounting of the coverslips
onto slides, cells were imaged using Zeiss AxioObserver microscope in the
UNMCCC Fluorescence Microscopy, with a Hamamatsu Flash 4 sCMOS camera
and a 63x 1.4 NA objective. Images were viewed and analyzed using SlideBook
(version 6.0.4).

Statistical analysis

Data are expressed as mean ± SEM. For comparison of groups, we used
the Student two-tailed t test. A level of P < 0.05 was regarded as statistically
significant.
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PREDICTION & VALIDATION OF INHIBITOR BINDING POCKET ON DNA
LIGASE I
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Timothy R.L. Howes, Rhys Brooks, Darin E. Jones, Cristian Bologa, Jeremy
Yang, Yoshihiro Matsumoto, Tudor I. Oprea and Alan E. Tomkinson

Abstract

With emerging evidence that abnormalities in DNA repair underlying the
genetic instability in cancer cells can be therapeutically targeted, there is a need
for inhibitors specific for different DNA repair enzymes and pathways. Since DNA
ligases are involved in nearly all forms of DNA repair as well as the joining of
Okazaki fragments during DNA replication, inhibitors of the three human DNA
ligases, which have distinct but overlapping cellular functions, are likely to have
utility as versatile probes of DNA repair in non-malignant and cancer cells and
the potential for development as anti-cancer therapeutics. Previously we
identified inhibitors with differing selectivity for the three human DNA ligases
using a structure-based approach. Here we have used an unbiased in silico
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screening approach of potential binding sites within the catalytic region of DNA
ligase I combined with information about the activity of candidate inhibitors from
the previous screen to predict the binding sites of a DNA ligase I-selective
inhibitor L82 and DNA ligase I/III selective inhibitor L67. To validate the binding
site, we showed that amino acid substitutions in DNA ligase I that are predicted
to prevent L82 binding, abolish its inhibitory activity. The definitive mapping of the
inhibitor binding will facilitate further rational design of inhibitors with increased
affinity and selectivity.

Introduction

The three human DNA ligases share a related catalytic core that is
composed of a DNA binding domain (DBD), a nucleotidyl transferase domain
(NTD) and an oligonucleotide/oligosaccharide binding domain (ODB)
(Ellenberger and Tomkinson 2008). Atomic resolution structures of the catalytic
cores of DNA ligases I and III complexed with nicked DNA revealed that these
domains, which adopt an extended conformation in the absence of DNA, encircle
the nicked DNA duplex with each of the domains contacting the DNA (Pascal,
O'Brien et al. 2004, Cotner-Gohara, Kim et al. 2010). While only the structure of
the catalytic core of DNA ligase IV has only been determined in the absence of
nicked DNA (De Ioannes, Malu et al. 2012, Ochi, Gu et al. 2013), the
conservation of amino acid sequence and similarities in secondary structure
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suggest that the DNA ligase IV catalytic core will adopt a similar clamp structure
when it ligates DNA.

The atomic resolution structure of DNA ligase I complexed with nicked
DNA was used to guide a structure-based screen for DNA ligase inhibitors
(Chen, Zhong et al. 2008, Zhong, Chen et al. 2008). An initial in silico screen
examined the predicted binding of small molecules to a DNA binding pocket
defined by the residues histidine 337, arginine 449 and glycine 453 within the
DNA ligase I DNA binding domain (DBD) (Pascal, O'Brien et al. 2004). Out of 1.5
million compounds, 233 candidate molecules were identified and then assayed
for activity in DNA joining assays with DNA ligases I, III and IV. Among the
candidates, 10 were active against DNA ligase I with some of these also
exhibiting activity against one or both other human DNA ligases in biochemical
and cell based-assays (Chen, Zhong et al. 2008, Zhong, Chen et al. 2008, Tobin,
Robert et al. 2012, Tobin, Robert et al. 2013). However, it has not been
demonstrated that these inhibitors do in fact bind to the targeted DNA binding
pocket. The definitive identification of the binding site would greatly enhance
efforts to design inhibitors with increased affinity and selectivity.

Here we have performed an unbiased in silico screen with the original 233
candidate molecules against binding pockets or receptors throughout the
catalytic core of DNA ligase I. Binding pockets were ranked based on the
predicted binding of molecules with activity in DNA joining activity. Using this
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approach, we predicted that two DNA ligase inhibitors identified in the initial
screen, L82 and L67 (Fig. 11A), have overlapping binding sites that are adjacent
to the originally targeted binding pocket (Chen, Zhong et al. 2008, Zhong, Chen
et al. 2008). The predicted binding site for L82 and its closely related derivative
L82-G17 (Fig. 11A) was confirmed by demonstrating that substitution of a key
residues within the binding site rendered the modified version of DNA ligase I
resistant to the inhibitor.

Results and Discussion

Ab inititio molecular modeling indicates the DNA ligase inhibitors L67 and
L82 have overlapping binding sites within the LigI DBD.

To ask whether one or more of the 10 DNA ligase I inhibitors identified in
the initial structure-based screen (Chen, Zhong et al. 2008, Zhong, Chen et al.
2008) are likely to bind to the targeted site, we carried out an unbiased screen of
over 1400 potential binding or receptor sites throughout the entirety of DNA
ligase I (PDB: 1X9N). Initially, the 233 candidate inhibitors identified in the
original in silico screen were docked onto approximately 300 potential binding or
receptor sites within the atomic resolution structure of human DNA ligase I
complexed with DNA (Pascal, O'Brien et al. 2004) using the OpenEye (OEChem
2012) suite of software. We hypothesized that, while it is unlikely that all 10
active inhibitors among the 233 candidates bind at the exact same location, it is
likely that several compounds will inhibit DNA ligase I activity by interacting with
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similar residues. Using the known data set of true positives (TPs) and true
negatives (TNs) among the initial 233 candidate compounds (Chen, Zhong et al.
2008, Zhong, Chen et al. 2008), we determined the relative ranking of inhibitors
using confusion matrices to evaluate potential binding sites. Specifically, the
number of the known active inhibitors among the top 10 chemicals predicted to
bind to a receptor, including the binding site used in the original computer aided
drug design (CADD) screen defined by residues histidine 337, arginine 447, and
glycine 453 within the DBD of DNA ligase I (Chen, Zhong et al. 2008, Zhong,
Chen et al. 2008), was used to rank receptors as likely binding site for the
inhibitors. Notably, the binding site used in the original screen defined by His
337, Arg 439, and Gly 453 (Chen, Zhong et al. 2008, Zhong, Chen et al. 2008)
had a TP rate of 10%, putting it in the bottom 61% of potential receptor sites
evaluated.

The highest scoring potential inhibitor binding sites were selected and
then modified as described in Materials and Methods to create new candidate
binding sites prior to re-evaluating in silico the 233 candidate compounds for their
ability to fit into the new, second generation, putative binding sites. After several
rounds of iteration, the receptor sites improved considerably with the average TP
rate increasing from 7% to 32% for the final putative binding pockets (Fig. 11B).
Residues involved in predicted enzyme-inhibitor interactions were identified for
each receptor site and those with the highest frequency of predicted interactions

75

Figure 11. Chemical Structures of DNA ligase inhibitors
(A) Structures and selectivity of three previously described small-molecule
inhibitors of human DNA ligases, L67, L82 and the L82 derivative, L82-G17. (B)
Utilizing an iterative process, clusters of inhibitors that were predicted to bind to
receptor/binding sites on DNA ligase I were identified. These were then scored
using confusion matrices, the results of which are shown here to illustrate the
improvement over four rounds of iteration.
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were chosen for further study. All selected residues, except Lys 744 and Glu 592,
were located within two regions of the DBD polypeptide, residues 336-351 and
445-448, that are in the same physical space (Fig. 12A). These residues are
shown in green with select residues identified for clarity whereas residues
involved in DNA binding, but not inhibitor binding residues are shown in pink
(Fig. 12A). One of the two residues with the highest frequency of predicted
interaction with inhibitors, His 337, formed part of the original binding site (Chen,
Zhong et al. 2008, Zhong, Chen et al. 2008) whereas the other one, Gly 448, did
not. Among the 10 DNA ligase I inhibitors (Chen, Zhong et al. 2008, Zhong, Chen
et al. 2008), L67, a DNA ligase I/III inhibitor, and L82, a DNA ligase I selective
inhibitor, are predicted to bind in each of the putative binding pockets used to
generate the list of critical residues whereas L113 and L190 bind in some, but not
all cases. Interestingly, there is significant overlap between the groups of
residues that are predicted to interact with L82 and L67 (Fig. 12B) with Asn 336,
His 337, Leu 338, Leu 347, and Ser 445 predicted to bind to both L67 and L82. In
contrast, Gly 339, Pro 340, Pro 341, Leu 345, Phe 408, Glu 456 and Phe 507,
are predicted to interact only with L67 whereas Val 349, Gly 350, Asp 351, Leu
446, Ser 447, and Gly 448 are predicted to interact only with L82 (Fig. 12B). In
space filling models with common residues indicated in orange, L67 specific
residues in purple and L82 specific residues in green, it appears that the binding
sites have share a central common region (Fig. 12C, left panel) and that, while
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Figure 12. Putative binding pockets of L82 and L67 predicted by unbiased
molecular modeling
(A) Ribbon diagram of the predicted inhibitor binding pocket of DNA ligase I
(gray). Inhibitor-interacting amino acids are shown in green, while DNAinteracting amino acids are shown in pink. (B) Frequency of predicted
interactions of amino acids from Asn336 to Lys541 with the inhibitors L82 and
L67. (C) Space filling model of the DNA ligase I DBD showing the predicted
conformations of L67 (magenta) and L82 (light green) in their overlapping binding
pockets are shown. The location of the pocket relative to the rest of the DBD is
shown on the left, while a magnified view of the pocket is shown on the right.
DNA ligase I residues that are predicted to interact with L67 (purple), with L82
(green) or with both L67 and L82 (orange) are indicated.
the binding sites of L67 and L82 overlap in this common region, they extend out
in opposite directions, making unique contacts with different residues (Fig. 12C).
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Figure 13. Comparing the
new predicted binding
pockets for L67 and L82 with
the binding pocket targeted
in the initial structure-based
screen for DNA ligase
inhibitors
(A) Space filling model of
DNA ligase I (gray) and DNA
(phosphodiester backbone,
orange and nitrogenous bases,
blue). Amino acids that are
predicted to interact with either
L67 or L82 have been
highlighted based on which
model they are implicated in.
Residues constituting the
binding pocket used in the initial
structure-based screen (Chen,
Zhong et al. 2008, Zhong, Chen
et al. 2008) are shown in
yellow, while residues
constituting the new predicted
binding pocket are shown in
red. Resides contributing to
both binding pockets are shown
in orange. (B) Predicted binding
locations and conformations of
L67 (magenta) and L82 (green)
in the two binding pockets. (C)
Binding of L82 and L67 in the
new predicted binding pocket in
the presence and absence of
DNA. DNA ligase I residues that
are predicted to interact with
L67 (purple), with L82 (green)
or with both L67 and L82
(orange) are indicated. In the
absence of DNA, the new
model predicts L82 to have a
new conformation (yellow),
while L67’s binding does not
change in the absence of DNA
(Fig. S4).
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Effect of DNA on the predicted binding pockets of the DNA ligase I/III
inhibitor L67 and the DNA ligase I-selective inhibitor L82.

In addition to differences in specificity, L67 and L82 also differ in their
mechanism of inhibition with L67 acting as a competitive inhibitor and L82 as an
uncompetitive inhibitor (Chen, Zhong et al. 2008, Zhong, Chen et al. 2008). In
order to gain insights into the contribution of DNA to the predicted binding sites,
additional, smaller receptor sites based on the predicted binding sites of L82 and
L67 were tested. This reduced the noise from other compounds docking
elsewhere. Initial studies focused on a receptor defined by Leu 335, Pro 340, and
Gly 352, that, like previously tested pockets, also included the electron density
contributed by the DNA that was co-crystallized with DNA ligase I (Pascal,
O'Brien et al. 2004). Under these conditions, L67 and L82 were ranked as the
first and second highest affinity compounds. This binding site (Fig. 13A, red) is
immediately adjacent to the original one used for computer aided drug design
(Fig. 13A, yellow). The predicted binding conformations of L67 (magenta) and
L82 (green) in the original CADD screen pocket (yellow), as generated in this
study, compared with the new pocket (red), are shown in Figure 13B. There is
greater overlap of the binding sites in the original CADD pocket than in the new
pocket (Fig. 13B). In accord with their different mechanisms of inhibition (Chen,
Zhong et al. 2008, Zhong, Chen et al. 2008), L82 consistently contacts the DNA
in the new binding pocket whereas L67 does not. The opposite is true in the
original binding pocket where L67 has nearly double the number of DNA contacts
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compared with L82. This is likely the result of its poor predicted binding at that
location.

When the docking assay was repeated with the new receptor in the
absence of DNA, the predicted binding affinity of L82 was reduced and its
predicted binding location shifted to a position that overlapped to a greater extent
with the predicted binding site for L67 (Fig. 13C). In contrast, the predicted
affinity and location of L67 binding was almost entirely unaffected by the absence
of DNA (Fig. S4). The predicted DNA-dependent and DNA-independent binding
modes of L82 are consistent with more recent kinetic data indicating that L82 is a
mixed inhibitor acting by both competitive and uncompetitive mechanisms
(Howes 2017).

Identifying key residues predicted to be involved in interactions with DNA
ligase inhibitors by in silico mutagenesis.

To further evaluate the role of residues predicted to be involved in the
interaction with L82, the homology modeling platform SWISS-MODEL (Bordoli,
Kiefer et al. 2009, Biasini, Bienert et al. 2014, Bienert, Waterhouse et al. 2017)
was utilized to generate three-dimensional structures of versions of DNA ligase I
with altered amino acid sequences using wild-type DNA ligase I as a template.
An identical receptor was then constructed for each mutant, defined by three
residues, Leu 335, Pro 340 and Gly 352, which did not move as a result of in
silico mutagenesis. More than 200 in silico mutants were evaluated, of which
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Figure 14. Utilizing in silico mutagenesis to prioritize biochemical assays
(A) Sequences of wild-type, consensus replacement, and single amino acid
substitution mutants. Mutated residues have been underlined. (B) Large scale in
silico single amino acid replacement mutagenesis shows that in this region, the
only mutations predicted to effect inhibitor binding are mutations of glycine 448.
approximately 40% were single amino acid replacements. Other types of in silico
mutations included the replacement of hairpin loops between regions of
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secondary structure with consensus sequences from different DNA ligases. For
example, hairpin loops from DNA ligase I (SLSG and GRLRLGLA, Fig. 14A)
were replaced with the corresponding hairpin loop sequences from DNA ligase IV
(MIIK and to KDLKLGVS, Fig. 14A), which is not inhibited by L82 and L67
(Chen, Zhong et al. 2008).

These amino acid replacements, which are located on the C terminal end
of helix 9, as well as on the loop that connects helices 9 and 10, resulted in a
decrease in the predicted binding of inhibitor L82, but no change for L67 (data
not shown). In addition, the predicted effects of substituting every residue from
Ser 445 to Ala 455 with at least four different amino acids were examined. Only
changes of Gly 448 significantly impacted the predicted binding of L82, but not
L67 (Fig. 14B) with replacement of Gly 448 with lysine resulted in a 10-fold
decrease in the predicted binding of L82, relative to other small molecules in the
known data set. The effect of this amino acid change is consistent with the
models developed for the binding of L82 and L67 as the extra bulk contributed by
the lysine residue occludes the L82 binding site (Fig. 15A), whereas this does
not impact the L67 binding site which is further away (Fig. 15B).

The recently described derivative of L82, L82-G17, that is more selective
for DNA ligase I than L82 and is an uncompetitive inhibitor (Howes et al, under
review) is predicted to bind in the same location as L82 (Fig. 15C). The only
differences between L82 and L82-G17 occur on the right-hand ring (Fig. 11A). In
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Figure 15. Replacement of glycine 448 with bulkier amino acids is
predicted to block the L82 but not L67 binding site
Space filling models of DNA ligase I (grey) showing; (A) predicted binding
sites of L67 (magenta) and L82 (green) in the wild type protein; (B) Effect of
replacing glycine 448 with a lysine residue (cyan) on the predicted L82 and L67
binding sites. (C) Predicted binding sites of L82 and L82-G17 (purple).
L82-G17 the -NO2 has been removed, and the hydroxyl group moves from a para
to a meta position. While both L82 and L82-G17 are predicted to bind to DNA
ligase I in the presence of DNA, L82-G17 is a predicted to bind better than L82,
in accord with the activities of these compounds in biochemical assays. This
mirrors the biochemical data presented in chapter 2 (Howes 2017).

Substitution of G448 with lysine or methionine confers resistance to
inhibition by L82 and L82-G17.

To validate the predictions of the in silico modeling, we purified G448K
and G448M versions of DNA ligase I. While the amino acid substitutions did not
significantly alter catalytic activity, these versions of DNA ligase I were resistant
to the inhibitory effects of L82 and L82-G17 whereas the inhibitory effect of L67
was not effected by either amino acid substitution (Fig. 16A). Since L82 and, to a
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greater extent, L82-G17 act
as uncompetitive inhibitors,
(Howes et al, under review)
we examined the effect of the
amino acid substitutions on
the formation of DNA-protein
complexes in the presence or
absence of inhibitors by
electrophoretic mobility shift
assay (EMSA) (Hellman and
Fried 2007). The competitive
Figure 16. Substitution of glycine 448 with
either methionine or lysine confers abolishes
effects of L82 and L82-G17 on DNA ligase I
(A) Effect of L82 and L67 on ligation by wild type
DNA ligase I and mutant versions in which
glycine 448 is replaced with either methionine
(G448M) or lysine (G448K). Results of three
independent assays are shown graphically and
expressed as a percentage of ligation in assays
with DMSO alone. (B) Effect of L67, L82 and L82G17 on the retention of labeled versions of wild
type DNA ligase I, a mutant version in which
glycine 448 is replaced with lysine (G448K) or
DNA ligase III by streptavidin beads liganded by
biotinylated DNA containing a single non-ligatable
nick. Results of three independent assays are
shown graphically and expressed as a
percentage DNA ligase I retained in assays with
DMSO alone.
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inhibitor L67 reduced the
binding of wild-type and
mutant versions of DNA
ligase I to the DNA (Fig. 16B)
whereas the uncompetitive
inhibitors, L82-G17 and L82
promoted the presence of
substrate bound ligase. In
contrast, neither L82-G17 nor
L82 increased the binding of
the mutant versions of DNA

Figure 17. Structural differences between the DNA binding domains of
human DNA ligases
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Figure 17. Structural differences between the DNA binding domains of
human DNA ligases
(A) Top left: Ribbon diagram showing the alignment of the DNA binding
domains of DNA ligase I (green), DNA ligase III (blue), and DNA ligase IV
(yellow). The red arrow highlights the area of greatest structural local
dissimilarity between the three human DNA ligases. Top right: space filling
model of DNA ligase I DBD, with docked L82 shown in white. Bottom left
and right, space filling models of DNA ligase III (blue) and DNA ligase IV
(yellow). Amino acids shown in red correspond to the loops indicated by the
red arrow in the upper left panel. (B) Sequential and structural similarities of
the DNA binding domains (DBD) and catalytic cores (AdD & OBD) of the
three human DNA ligases. (C) Local RMSD of paired helices within the
DBDs of the three human DNA ligases. The loops connecting helices 1-2, 34, 5-6, 7-8, 9-10, and 11-12 are located on the DNA binding side of the
DBD, while all the others are on the exterior of the protein. Helix pair 3-4,
indicated by the red arrow, represents the area of greatest structural
dissimilarity in the DNA binding surface between DNA ligases I and III.

ligase I to DNA. Together these biochemical results validate the predictions from
our in silico modeling of inhibitor binding.

Despite sequence divergences, the secondary structures of the DNA
binding domains of the human DNA ligases are highly conserved.

The identification of the inhibitor binding site in DNA ligase I prompted us
to examine the comparable regions of DNA ligase III and IV with the expectation
that there will be differences that underlie the selectivity of existing inhibitors and
may be exploited to guide the design of more selective inhibitors for each of the
three human DNA ligases. While the DBDs of the mammalian DNA ligases are
more recent, evolutionarily speaking, (Ellenberger and Tomkinson 2008) and
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therefore more diverse than the adenylation (AdD) and
oligosaccharide/oligonucleotide binding (OBD) domains, they do appear to be
structurally similar (Fig. 17A). To better understand the differences and
similarities between the catalytic regions of the three human ligases, each
isoform was compared to the other two using protein structure homology
modeling in conjunction with analysis of amino acid sequence homology using a
BLOSUM62 substitution matrix. The OBD and AdD domains, which contain the
conserved motifs that define the nucleotidyl transferase superfamily (Shuman,
Liu et al. 1994, Shuman and Schwer 1995), have, as expected, a high degree of
sequence identity and predicted structural homology. In contrast, the DBDs have
only about 22% amino acid similarity. Nonetheless, these domains appear to still
have a reasonably high level of structural homology, as shown by the global
model quality estimation (GQME) (Fig. 17B). To corroborate this point, NCBI
BLASTP searches limited to Homo sapiens, using either the DBDs or the
AdD/OBD catalytic cores as the query sequences yielded very different results,
with the catalytic cores but not the DBDs returning other DNA ligases as similar
in sequence (data not shown).

While the human DNA ligase DBDs are structurally similar (Fig. 17A), they
are some local differences. By analyzing the root mean square deviation (RMSD)
between paired helices of different human DNA ligases, we identified the loop
between the third and fourth helix as the part of the DBD that is most different
between DNA ligases I and III (Fig. 17C). This loop, indicated with red in Figure
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17A, is the major contributor to the L82 inhibitor binding pocket described above.
While this loop is longer in DNA ligase I compared with the other DNA ligases, it
forms a more compact structure in DNA ligase I compared with DNA ligases III
and IV. These differences in local structure presumably underlie the selectivity of
L82 for DNA ligase I and suggest that the comparable regions of DNA ligases III
and IV are less amenable to small molecule binding.

In summary, we have used an unbiased modeling approach to predict the
binding sites of DNA ligase inhibitors that were identified previously by an in silico
structure-based approach (Chen, Zhong et al. 2008, Zhong, Chen et al. 2008).
These studies predicted that the DNA ligase I selective inhibitor, L82, and the
DNA ligase I/III inhibitor, L67, occupy overlapping binding pockets that are
immediately adjacent to the binding pocket targeted in the initial structure-based
approach (Chen, Zhong et al. 2008, Zhong, Chen et al. 2008). We have validated
the binding pocket of L82 by demonstrating that replacing a glycine residue with
bulkier residues that occlude the binding pocket abrogates the inhibitory activity
of L82. The definitive identification of the inhibitor binding site will facilitate the
rational design of more selective inhibitors. Furthermore, the construction of cell
lines that express inhibitor-insensitive versions of DNA ligase I will play a critical
role in demonstrating that cellular responses induced by exposure to the DNA
ligase I selective inhibitors, L82 and L82-G17 are in fact due to inhibition of DNA
ligase I rather than off-target effects.
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Materials & Methods

Chemicals

The chemicals L67 (IUPAC: 2-[(3,5-dibromo-4-methylphenyl)amino]-N'-[(2hydroxy-5-nitrophenyl)methylidene]acetohydrazide), L82 (IUPAC: 4-chloro-5-{2[(4-hydroxy-3-nitrophenyl)methylidene]hydrazin-1-yl}-2,3-dihydropyridazin-3-one,
and L82-G17 (4-chloro-5-{2-[(3-hydroxyphenyl)methylidene]hydrazin-1-yl}-2,3dihydropyridazin-3-one) were done as described previously (Howes 2017).

Targeted Mutagenesis and Protein Purification

Oligonucleotides for DNA substrates, and mutagenesis were designed in
Serial Cloner (version 2.6.1) and ordered from Integrated DNA Technologies
(IDT, Iowa, USA). Annealing temperatures for mutagenesis using the polymerase
chain reaction (PCR) were calculated with the aid of OligoCalc (Kibbe 2007).
PCR was performed using a Bio-Rad MyCycler thermal cycler. and
oligonucleotides

DNA Ligation Assays

In the fluorescence-based ligation assay (Chen, Pascal et al. 2006, Chen,
Ballin et al. 2009), purified DNA ligase I (500 fmol) was incubated in the presence
or absence of either L82 or L82-G17 with fluorescent nicked DNA (1 pmol) for 15
minutes in a final volume of 20 µL containing 60 mM Tris–HCl [pH 7.4], 50mM
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NaCl, 10 mM MgCl2, 5 mM DTT, 1 mM ATP, 50 μg/ml BSA, and 4% DMSO) at
25 °C. All controls and blanks contained an equivalent volume of vehicle DMSO.
Following incubation, reactions were further diluted to 200 μL with a 30-fold molar
excess of an unlabeled oligonucleotide (5’TAGGAGGGCTTTCCTCCTCACGACCGTCAAACGACGGTCA) identical in
sequence to the ligated strand in 10 mM Tris–HCl pH 7.4, 50 mM KCl, 1 mM
EDTA and 5 mM MgCl2 and then heated to 95 °C for 5 min. After cooling to 4 °C
at a rate of 2 °C/min, fluorescence at 519 nm (excitation at 495 nm) was
measured immediately using the Synergy H4 microplate reader (BioTek). Data,
including Michaelis-Menten kinetics, was analyzed through GraphPad Prism
software.

DNA Binding Assays

For electrophoretic mobility shift assays, a radiolabeled 73 bp linear
duplex with a single nick was generated as above except that there was a
dideoxycytosine residue at the 3’ terminus of the nick (Pascal, O'Brien et al.
2004, Chen, Zhong et al. 2008). Putative inhibitors, purified DNA ligase I and the
nicked substrate (amounts) were incubated in 50 mM Tris pH 7.5, 15 mM NaCl, 1
mM DTT, 0.2mM ATP, 0.005 mg/mL BSA, 5 mM MgCl2, 8.75% glycerol and
0.5% DMSO for 30 minutes. After electrophoresis through a 5% non-denaturing
polyacrylamide gel using 0.5 x TBE pH 8.3 as running buffer, labeled
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oligonucleotides were detected by phosphorimager analysis and imaged as
described above.

Compound Docking

The ability of small molecules to bind to DNA ligases was evaluated in
silico using the OpenEye suite of software, VIDA, Make Receptor, Omega and
OEDocking in collaboration with Dr. Tudor Oprea’s group. Small molecules were
generated in the SMILES format using MarvinSketch, (version 14.9.8.0). For any
situation in which multiple stereoisomers were possible, all were used. Chemical
binning and hierarchical clustering was done using the online tool ChemMine.
Figures were rendered with PyMol (version 1.3). Small molecule structures were
consolidated using VIDA (version 4.2.1), and multiconformers of every small
molecule were generated using Omega (version 2.5.1.4), with a maximum of 500
conformations per molecule. These multiconformer files were used by the FRED
(Fast Rigid Exhaustive Docking) function of OEDocking (version 3.0.1) to predict
each compound’s ability to interact with potential receptor sites on a given
protein. Receptor sites were generated using Make Receptor (version 3.0.1),
generally using 2-4 amino acids to define the potential receptor site. The results
of the docking assays were exported as a spreadsheet, for combination and
analysis in Microsoft Excel 2013 (version 15.0.4797.1003). Each receptor was
evaluated using confusion matrices, allowing for a quick and iterative process of
putative receptor site improvement. In addition to assessing true positives and
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negatives, we also evaluated confusion matrices by the geometric mean, (Fig.
11B) a unitless measure that is useful when the number of negatives is much
greater than the number of positives (Kubat, Holte et al. 1998).

Receptor iteration was done by performing any of the following methods:
expansion, contraction, translation, rotation, and in the presence or absence of
DNA. Additionally, receptors were created from individual domains, as well as the
entire available DNA ligase I structure. The exact number of docking sites tested
in Figure 11B for round 1, round 2 and round 3 are 334, 428 and 657
respectively. Figures including protein, DNA and small molecules were rendered
with PyMol (version 1.3) (DeLano 2002).

Interaction Reports

Protein-inhibitor interaction reports were generating using a built-in
function of the FRED software. All data generated from the Leu335, Pro340,
Gly352 receptor is the result of testing seven different slight variations of the
same receptor to reduce the impact of one-off interactions. Interaction reports
were converted to text documents before conversion to spreadsheets.

Homology Modeling

Initial evaluation of putative critical residues was done by in silico
mutagenesis. Specifically, the raw amino acid sequence of DNA ligase I was
altered in a text document prior to utilizing the homology modeling platform
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SWISS-MODEL (Bordoli, Kiefer et al. 2009, Biasini, Bienert et al. 2014) to quickly
and easily generate a probable three-dimensional structure of the altered protein,
using wild-type ligase DNA ligase I (PDB: 1X9N) as the template. NCBI (National
Center for Biotechnology Information) BLASTP (Basic Local Alignment Search
Tool – Protein) searches were performed using the NCBI web interface
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) and aligning the two amino acid
sequences (Altschul, Gish et al. 1990).

Statistical analysis

Data are expressed as mean ± SEM. For comparison of groups, we used
the Student two-tailed t test. A level of P < 0.05 was regarded as statistically
significant.
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CHAPTER 4

SUMMARY, CONCLUSION & FUTURE DIRECTIONS

Summary

The work presented in this dissertation has identified the small molecule
DNA ligase I-selective inhibitor L82-G17. L82-G17 represents a substantial
improvement over its parent compound, L82. L82 was a first-generation ligase
inhibitor published in 2008 by the Tomkinson lab (Chen, Zhong et al. 2008,
Zhong, Chen et al. 2008). L82-G17 is an uncompetitive LigI-selective inhibitor,
proven to reduce the survival of wild type cells to a significantly greater degree
than isogenic LIG1 null cells. Beyond identifying improved DNA ligase inhibitors, I
have also identified the pocket to which these inhibitors bind in the LigI DBD.
Furthermore, during my graduate work, I found it helpful to compile data about
specific ligation mutations and important residues, as well as maintaining a
master list of ligase crystal structures. These were invaluable to me during my
work, and I have included some of those lists here.

The hybrid structure of this dissertation means that chapters two and three
are presented in their original published form, only modified for format. However,
these two papers do not reflect the entirety of my research on DNA ligase
inhibitors. Additional research was done into characterizing not only the ligase
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inhibitors, but also the inhibitor binding site that was identified in chapter three of
this document.

Key structural elements of the LigI DBD confer sensitivity to L82.

As was the case with Gly 448, the sequence of the loops is less important
than the shape that sequence imparts. Examination of each ligase’s tertiary
structure shows that the equivalent area to the binding pocket in LigI yields more
insight into L82’s inability to inhibit either DNA ligase III or IV. Assaying the L82
binding pocket sizes show that these differences result in significantly less
potential inhibitor binding surface area in LigIII than in LigI. The ratio of examined
volume to predicted pocket size predicts that an average of 19.7% +2.5 of space
in LigI is open enough for small molecule binding, compared to only 15.6% +1.2
in LigIII (Fig. 18A). In accordance with the binding loop sizes (Fig. 17A), LigIV
falls between these two, with a pocket area of 16.8% +2.1. However, we refrain
from drawing too many conclusions from comparisons between the x-ray crystal
structures of LigI/III and LigIV, as LigI/III were co-crystallized with DNA, while
LigIV was not. Aligning each DBD via helix 4 reveals that this spatially equivalent
site encroached upon by helix 9 in both LigIII and LigIV (Fig. 18B). Furthermore,
the similar to how the G448K and G448M mutations both prevented L82 binding,
(Figures 15B and 16) helix 9 of LigIII and LigIV have sidechains that protrude
into what would be the L82 binding pocket (Fig. 18C). This provides potential
justification for the L82’s selectivity for DNA ligase I.
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Figure 18. DNA Ligase III lacks the space for L82 to bind
(A) Over equivalent volumes of LigI and LigIII, LigI consistently has more surface
area exposed for small molecules to fit in. This is true both in the presence and
absence of DNA, data shown is in the absence of DNA. Green circles – LigI, blue
triangles – LigIII, yellow squares – LigIV. (B) Human ligase DNA binding
domains, aligned via the backbone of helix 4. Green – LigI, blue – LigIII, yellow –
LigIV. The structure of helix 9 encroaches on the L82 binding pocket in both LigIII
and LigIV. The effects of the tertiary structure are further exacerbated by the
sequence, (C) in both LigIII and LigIV side chains protrude into the space that
L82 binds in LigI. (D) His 331 (white) obfuscates the area equivalent to LigI’s L82
binding pocket. L82 shown in yellow. (E) H331G in silico mutation (white)
increases results in L82’s predicted binding to the LigIII DBD. Bound L82 shown
in green.
The binding loop of LigI was replaced with that of LigIII by both simple
replacement and homology modeling. Furthermore, the LigIII equivalent to Gly
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448, His 331, was mutated in
silico to a glycine, removing the
sidechain. While there was some
negative effect on the predicted
binding of L82, that effect was
relatively small to the positive
effect on L82 binding that
removing the sidechain of His 331
had on L82’s affinity for DNA
ligase III (Fig. 18 D&E). in silico
experiments show that deleting
the histidine side chain, which
takes up approximately 100 Å3,
opens the space needed for L82

Figure 19. Spectroscopic profiles of LigI
inhibitors
Analyzing the colour of L67, L82 and L82G17. (A) The chemical differences between
these compounds produce different colours.
(B) UV spectra of L67, L82 and L82-G17
was used to confirm that the integrity of
structures long after synthesis.

binding, similar to what is
observed in LigI. H331G in silico mutation results in L82 binding to LigIII in our
predictive model. These two residues, His 331 and Lys192 in LigIII and LigIV
respectively, appear to be the reason that L82 is ineffective, as they protrude into
the cavity created by the L82 binding loop which connects helices 3 and 4 of the
DBD. Studying the predicted mutant structures and the inhibitor binding,
mutations of glycine 448 appear to obstruct L82’s preferred binding site (Fig.
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14A). Supporting this
argument is that the
equivalently located amino
acid to glycine 448 on DNA
ligases III covers the L82
Figure 20. Ligase inhibitors do not kill or
impede the growth of bacteria
Bacteria transformed with plasmid pUC19 were
treated with 100 µM doses of ligase inhibitors
(circles), an equivalent ratio of DMSO (triangles),
or hydrogen peroxide (H2O2, squares). Only
hydrogen peroxide made any difference to
bacterial growth.

binding site.

Colour and Spectroscopic
Profile

Also investigated was
the nature of the colour change observed in L82-G17 from L82 and L67. The UVvis profile of L67, L82, and L82-G17 were analyzed. L67 has a visible spectrum
peak of 434 nm, consistant with its more yellow colour. L82 and L82-G17 have
absorbance peaks at 456 nm and 468 nm, respectively, which impart an orange
colour (Fig. 19A). As expected, the UV spectra of L82 and L82-G17 are nearly
identical, which follows their structural similarity (Fig. 19B). The main difference
in the L82 and L82-G17 UV spectra occurs around 265 nm, at which point L82G17 absorbs less than L82. This is consistant with the loss of a benzene bound NO2 group. The differences between L67 and L82 in the 250-300 nm range is
due to the differences in the chain linking the two rings. The shoulder at 325 nm
is caused by the two bromines on the left ring of L67 (Fig. 3) (Schirmer 1990,
Linstrom and Mallard 2001).
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Ligase Inhibitors Have No Effect on Prokaryotic
Cells

Off target effects can be difficult to identify.
One potential complication that could result from
poor solubility is that the compounds themselves
were effecting the cellular membrane by precipitating
out of solution. No inhibitor had any effect on
bacterial cell growth or proliferation (Fig. 20).

Modeling Data Supports Recent Findings on
SCR7

Figure 21. The many faces
of SCR7

Recently published data has called into
question both the structure and the potency of SCR7
(Srivastava, Nambiar et al. 2012, Greco, Conrad et
al. 2016, Greco, Matsumoto et al. 2016). Three

SCR7 is a reported, and
debunked LigIV inhibitor
with several reported
structures (A) SCR7, (B)
SCR7-G, and
(C) SCR7-R.

structures of SCR7 have been identified, in addition to the original SCR7, (Fig.
21A) there is also SCR7-G (Fig. 21B) and SCR7-R (Fig. 21C). Each of the
reported structures of alleged ligase inhibitor SCR7 were docked into the
previously established binding sites. The calculated binding affinity was
established relative to other known compounds, as described in chapter 3.
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In addition, efforts were
made to recreate structure that
the original authors docked SCR7
onto. However, Srivastava et al.
reference the PDB structure
2XEO as the basis for their
homology modeling of DNA ligase
IV: “The structure of DNA
containing DSB was retrieved
from PDB database (2XEO).”
(Srivastava, Nambiar et al. 2012)
2XEO references a withdrawn
structure of PatL1, a human
mRNA decapping enzyme. I was
able to find the paper that this
structure was submitted with as
well as the associated structure
Figure 22. PatL1 is not at all similar to the
DBD of LigIV

2XES. 2XES is also an x-ray
crystal structure and has the

(A) PatL1 x-ray crystal structure, PDB: 2XEO.
same title as 2XEO, “Human
(B) DNA binding domain of DNA ligase IV,
PDB: 3W1G. (C) Alignment of PatL1 and
LigIV DBD yields an RMSD of over 20; these PatL1 C-terminal domain (loop
structures are not similar.
variant)” and was submitted one
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day after, May 16th, 2010. It does not contain DNA (Braun, Tritschler et al. 2010).
As was expected, the structures of LigIV and PatL1 are highly dissimilar. A
simple comparison between LigIV’s DBD and 2XEO is 21.9 RMSD, which fits
with how different the structures appear based on a visual comparison (Fig. 22).
The LigIV DBD and the PatL1 structure are highly dissimilar, with an RMSD
greater than 20. Initially beleiving “2XEO” to be a typo, a list of all published
ligase structures was compiled (Table 2) (Subramanya, Doherty et al. 1996,
Singleton, Håkansson et al. 1999, Lee, Chang et al. 2000, Odell, Sriskanda et al.
2000, Sibanda, Critchlow et al. 2001, Gajiwala and Pinko 2004, Pascal, O'Brien
et al. 2004, Srivastava, Tripathi et al. 2005, Doré, Furnham et al. 2006, Nishida,
Kiyonari et al. 2006, Pascal, Tsodikov et al. 2006, Nandakumar, Nair et al. 2007,
Vijayakumar, Chapados et al. 2007, Pinko 2008, Han, Chang et al. 2009, Kim,
Kim et al. 2009, Wu, Frit et al. 2009, Cotner-Gohara, Kim et al. 2010, Cuneo,
Gabel et al. 2011, Mills, Eakin et al. 2011, De Ioannes, Malu et al. 2012, Ochi,
Wu et al. 2012, Petrova, Bezsudnova et al. 2012, Surivet, Lange et al. 2012,
Wang 2013, Murphy-Benenato, Wang et al. 2014, Unciuleac, Goldgur et al.
2017). No structure of any DNA ligase has a PDB ID similar to 2XEO, particularly
none of the four structures that contain DNA: 1X9N, 2OWO, 3L2P, 4GLX.

In the interest of a thorough investigation, all SCR7 structures were
docked onto multiple pockets of PatL1 crystal structure 2XES. SCR7 is not
predicted to bind to PatL1, nor is L67, L82, L189 or any of the other previously
described DNA ligase inhibitors (Zhong, Chen et al. 2008) or L82-G17.
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Table 2. Compilation of DNA ligase crystal structures
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Summary Remarks

Compiling the collective knowledge of all ligase structure and LigI
mutations in one place is also particularly useful for anyone beginning or
continuing work on DNA ligases, particularly any structural biology work. The first
crystal structure of a DNA ligase was published in 1996 (Subramanya, Doherty et
al. 1996). There are now 45 x-ray crystal structures of DNA ligases published,
(Table 2) covering a 19 different species (Subramanya, Doherty et al. 1996,
Singleton, Håkansson et al. 1999, Lee, Chang et al. 2000, Odell, Sriskanda et al.
2000, Sibanda, Critchlow et al. 2001, Gajiwala and Pinko 2004, Pascal, O'Brien
et al. 2004, Srivastava, Tripathi et al. 2005, Doré, Furnham et al. 2006, Nishida,
Kiyonari et al. 2006, Pascal, Tsodikov et al. 2006, Nandakumar, Nair et al. 2007,
Vijayakumar, Chapados et al. 2007, Pinko 2008, Han, Chang et al. 2009, Kim,
Kim et al. 2009, Wu, Frit et al. 2009, Cotner-Gohara, Kim et al. 2010, Cuneo,
Gabel et al. 2011, Mills, Eakin et al. 2011, De Ioannes, Malu et al. 2012, Ochi,
Wu et al. 2012, Petrova, Bezsudnova et al. 2012, Surivet, Lange et al. 2012,
Wang 2013, Murphy-Benenato, Wang et al. 2014, Unciuleac, Goldgur et al.
2017). as well as several nuclear magnetic resonance (NMR) structures of ligase
fragments (PDB ID’s: 1L7B, 1IN1, 1IMO, 1UW0, 2E2W, and 2LJ6) (Krishnan,
Thornton et al. 2001, Kulczyk, Yang et al. 2004, Sahota, Goldsmith-Fischman et
al. 2004, Nagashima 2006, Natarajan, Dutta et al. 2012). Of these, only four,
1X9N, 2OWO, 3L2P and 4GLX show the ligase complexed with DNA. 1X9N and
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3L2P are structures of LigI and LigIII, respectively, while the other two are of
Escherichia coli ligase, LigA (Table 1).

The active site lysine of human DNA ligase I was identified (Tomkinson,
Totty et al. 1991) and then confrimed in 1991 by mutagenesis (Kodama, Barnes
et al. 1991). Many other studies have examined the effects of various mutations
on the function of DNA ligase I. I have endeavoured to catalog the effects of
every published LigI mutation in Table 3. Negative data, such as glycine 363,
were also included; these residues may or may not be critical in ways yet to be
determined. Two residues, Gly 448 and Gly 571 were each found to be mutated
once in the COSMIC database. “New data” indicates any data generated from
my graduate work. Furthermore, several conclusions have been drawn from
either observation of the three-dimensional structure of LigI, or by computational
means. Every residue that is predicted to be important to LigI structure or
function has been catalogued in Table 4. Two residues, Glu 621 and Arg 871
were each found to be mutated once in the COSMIC database (Forbes, Beare et
al. 2015).

105

Table 3. Biochemically tested DNA ligase I mutants

Table 4. Residues of DNA ligase I implicated by computational means
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Conclusion

As stated at the end of chapter 1, I listed two specific aims in my thesis
proposal, each with three sub-aims. I believe that both of these proposed
research goals were achieved. During my time in graduate school, I have
published one book chapter, three papers, with two that have been submitted for
publication:
•

Chumsri, S., Howes, T., Bao, T., Sabnis, G., Brodie, A. Aromatase,
aromatase inhibitors, and breast cancer. J Steroid Biochem & Mol
Biol. 2011;125:13-22. (Chumsri, Howes et al. 2011)

•

Chumsri, S., Sabnid, G.J., Howes, T., Brodie, A.M.H. Aromatase
inhibitors and xenograft studies. Steroids. 2011;8:730-735.
(Chumsri, Sabnis et al. 2011)

•

Howes, T.R. and Tomkinson A.E. DNA Ligase I, the Replicative
DNA Ligase. Subcell Biochem. 2012;62:327-341. (Howes and
Tomkinson 2012)

•

Tomkinson, A.E., Howes, T.R.L., Wiest, N.E. DNA ligases as
therapeutic targets. Transl Cancer Res. 2013;2:203-214.
(Tomkinson, Howes et al. 2013)

•

Howes, T.R.L., Sallmyr, A., Brooks, R., Greco, G.E., Jones, D.E.,
Matsumoto, Y., Tomkinson, A.E. Characterization of an
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uncompetitive inhibitor of DNA ligase I. (under review) (Howes
2017)
•

Howes, T.R.L., Jones, D.E., Bologa, C., Yang, J., Matsumoto, Y.,
Oprea, T.I., Tomkinson, A.E. Prediction and Validation of Inhibitor
Binding Pocket on DNA Ligase I. (submitted) (Howes 2017)

Aim 1

The first stated aim was to identify determinants of structure, activity and
specificity of DNA ligase inhibitors by characterizing derivatives of the DNA ligase
I inhibitor, L82, and the DNA ligase I/III inhibitor L67. This was to be achieved via
assessing the chemical derivatives of L67 and L82 that the Tomkinson lab had in
it’s possession, for their ability to inhibit nick ligation by LigI or LigIII. The results
of this step are shown in Figure 4A and Figure 5, and identified L82 derivative
L82-G17 as superior to L82, being more effective against LigI and less effective
against LigIII. This was followed by an a comprehensive examination of the
properties of each inhibitor, which identified three subgroups of ligase inhibitors:
vinyl-, hydrazine-, and hydrazone-linked (Fig. 10). It was hypothesized that there
would be chemical differences between active inhibitors and inactive inhibitors,
and the analysis revealed that a meta polar group was crucial to inhibition
(position 8 or 10 in Figure 10C). Other chemical properties of inhibitors were also
determined, such as solubility and its UV-vis spectroscopic profile were also
determined.
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The final part of specific aim 1 was to examine the effects of L82-G17 in
cell culture models. The proposal calls out a few techniques by name, such as
colony assays (Fig. 8 A&B) and BrdU incorporation (Fig. 7A). The third
technique specifically mentioned is iPOND, or isolation of proteins on nascent
DNA, (Sirbu, Couch et al. 2011) a technique that allows for spatiotemporal
analysis of replication fork dynamics. However, it was determined that while it is
an interesting and powerful technique, it would be more beneficial to return to
iPOND with a more potent DNA ligase I inhibitor.

My work has shown that L82-G17 specifically inhibits DNA ligase I both
biochemically, and in cell culture models, and has identified the underlying
structural commonalities behind those compounds that inhibit DNA ligase I.

Aim 2

The second specific aim in the thesis proposal for this work was proposed
using molecular modeling approaches to predict a binding site for the current
pool of DNA ligase inhibitors and make specific amino acid substitutions to test
these predictions. The L82 binding site, shown in Figure 12C, was predicted and
identified by screening the entirity of LigI in silico for potential ligase inhibitor
binding sites. Potential small-molecule binding pockets were evaluating with
confusion matrices, using the known data set of previously biochemically tested
compounds to look for clusters of true positives. The best candidates were then
selected and modified in an iterative process. The result of this was that a region
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that returned L67 and L82 as the top two hits in the presence of DNA, and only
L67 in the absence of DNA, mirroring what we knew to be biochemically true
about the inhibitors.

Using this predicted binding pocket, I identified all of the amino acids that
were predicted to be involved with inhibitor binding. In order to prioritize these for
biochemical mutagenesis studies, I performed large scale single amino-acid
replacements in silico, mutating not only those residues, but those around them
as well. During this time, I also did consensus replacement mutations of LigI,
replacing the loop connecting helices 3 and 4, with that of LigIV. These mutants
were resistant to L82 inhibition. This supported the data generated from in silico
mutagenesis, which identified glycine 448 as the residue that, when mutated, had
the largest effect on L82 binding (Fig. 14B). Glycine 448 mutants were generated
and purified by FPLC. These were also protected from inhibiton by L82 (Fig. 16).

Biochemically validating the computational model allowed me to use that
model as the basis for further invesitation. I began by analyzing why L82 bound
to LigI but not LigIII or LigIV. It is a long established fact that there is a large
degree of amino acid sequence homology between all DNA ligases (Doherty and
Suh 2000). It has also been qualitatively observed that the structures of ligase
DNA binding domains are highly similar, despite fairly large differences in amino
acid sequence. I was surprised to learn that this had not been backed up
quantitatively, however. In order to determine what makes differences exist in the
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DBDs, it is important to know just how similar they are. As expected, the catalytic
core (AdD & OBD) of each ligase is both highly similar, both sequentially and
structurally, however, the DBDs were also similar on a strucrual level, despite
their differences in sequence (Fig. 17B). Most importantly, the ratio of sequence
to structural homology meant showed that the DBDs were more structurally
similar, relative to their sequnce identity, than the catalytic cores were. The loop
between helices 3 and 4, which defines most of the L82 binding pocket, is the
area of greatest structural dissimilarity on the DNA binding surface of the DNA
binding domains (Fig. 17 A&C).

Further using the L82 binding model presented here, I was able to show
that, in the equivalent region of LigIII, there was less space availiable for inhibitor
binding. The ratio of calculated volume for small molecule binding in LigIII was
significantly less than that of LigI, over a range of assayed sizes. Additionally,
LigIII’s equivalent to glycine 448, histidine 331, protruded into the area of that
would be the L82 binding site. The difference in volume between these two
equivalent areas being assayed was, on average, 126 Å 3, the volume of a
histidine side chain is approxinately 100 Å3. Based on this, I tested a H331G in
silico mutant, and found that this was predicted to restore L82 binding (Fig. 18).
Based on this, I am highly confident that we have located the site of L82
interaction and inhibition.
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Future Directions

The data presented here represents significant steps forward in our
understanding of ligase inhibition. However, there is always more research that
can be done. In chapter one, I mention that LIG1, LIG3 and LIG4 were identified
as mutated at a rather low rate of 0.69%, 0.49% and 0.58%, respectively
(Forbes, Beare et al. 2015). Data on protein expression, however, is not as easy
to come by, or to analyze. I believe that expression levels of ligases in cancer
cells represents an area of investigation that would identify cancers and cancer
cell lines that would be ideal targets for ligase inhibiton.

Complementing cells with the L82-resistant ligase mutant

The most immediate next step for continuing studies with L82 and L82G17 would be to transfect LigI-resistant mutant G448K into LigI deficient cells.
This would show both that L82 acts directly on L82 inside the cell, but also
identify any toxicity that may be the result of off-target effects. I have previously
attempted to show this using thermal titration of L82 treated cells, (Jafari,
Almqvist et al. 2014) however, this would be a superior approach. I hypothesize
that transfecting LIG1-G448K into DNA ligase I deficient cells would resore L82
sensitivity.
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Attenuating DNA Ligase III to L82 inhibition

In Figure 18 I propose a rational behind the ineffectiveness of L82 and
L82-G17 on DNA ligase III. However this hypothesis, while backed up by in silico
data, still requires biochemical testing. I would evaluate this mutation the same
way that LigI mutations were tested in chapter three. Express and purify the
H331G LigIII mutant from bacteria, and then assay its ability to both bind to and
seal nicked DNA by ligation and electrophoretic mobility shift assays. I
hypothesize, based on the data presented above, that removing the sidechain of
histidine 331 would attenuate LigIII to inhibition by L82.

Sequential and Structural Conservation of DNA Ligases

In chapter three I touched briefly on how the structures of DNA ligases are
more structurally similar than their amino acid sequences indicated. This is
something that has been observed since the structures were determined, but had
not been addressed quantitatively. Further investigation could be done into the
structural similarity, not just between the 49 published structures of DNA ligases,
but also the 8 full and 17 partial structures of mRNA capping enzymes availiable
on the Protein Data Bank (Berman, Westbrook et al. 2000). These degrees of
structural similarity would then be compared with the amino acid sequence
similarity, such as in Figure 17B, but on a larger scale. This kind of knowledge
has the potential to be extremely useful in both designing specific inhibitors, and
evaluating inhibitor mechanisms of action.
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Delivering Ligase Inhibitors

Both L67 and L82, as well as L82-G17, have limited solubility in acqueous
solutions. While both readily dissolve into DMSO at 50-75 mM, DMSO is not
ideal for measuring any biochemical activity. Several buffer systems were tested
for their ability to solubilize these ligase inhibitors, including PBS, HEPES, and
Tris, at different pH values. Inhibitors were more readily soluble in these, versus
dH2O

alone. The solution that resulted in the greatest solubility of L82 and L67

was Tris pH 7.5 (data not shown). Also evaluated was the solubility of these
inhibitors in ethanol as compared to DMSO. Both L82 and L67 were significantly
more soluble in DMSO.

In collaboration with Dr. Eric Carnes at the University of New Mexico’s
department of chemical and nuclear engineering, we evaluated the effects of
using nanocarriers to deliver L67. Three different types of nanocarriers, targetedand untargeted-DOPC, as well as DoTAP (Butler, Durfee et al. 2016). These
nanoparticles were effective at delivering L67 and increased its toxicity (data not
shown). Ultimately, it was determined that L82 was the primary focus of my
research, and this avenue of investigation was halted. It remains, however, an
area of DNA ligase inhibitor research with a great deal of potential, and one that
other research groups are also persuing (John, George et al. 2015).
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Potential New Ligase Inhibitors

The small-molecule ligase inhibitors that we currently have are limited in
several ways. They are poorly soluble in aqueous conditions, and are effective
only in the low micromolar range. These solubility issues have already caused
trouble for our lab, impairing both NMR and x-ray crystallographic studies. Using
the ligase inhibitor binding site identified by molecular modeling, over a thousand
derivatives of ligase inhibitors L67, L82 and L82-G17 have been docked into the
inhibitor pocket to assess their potential for ligase inhibition. In addition, over six
thousand small molecules between 300 and 400 molecular weight, were pulled
from PubChem and modeled into the inhibitor binding pocket on DNA ligase I.
Additionally, molecules of 75% of greater similarity to existing inhibitors, or in
silico derivatives were pulled from the inventories of various chemical vendors
such as ChemBridge. These chemicals were docked into the inhibitor binding site
identified in chapter 3, and the top results were, in an iterative process, modified
and re-docked into the pocket. The chemicals shown in Figure 23A are the
results of this screening process. While several of these do not pass Lipinski’s
rule of 5 (Lipinski 2000) they are important in that they show it is theoretically
possible to create an inhibitor, TH5-32-2-11 (Fig. 23B), that binds in both the L82
and L67 pockets. This compound, or one like it, has the potential to both be an
extremely potent and a highly specific inhibitor designed for ligase I.
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Figure 23. Potential DNA ligase I inhibiting compounds identified by in
silico experiments
(A) Nine different potential ligase inhibitors with binding superior to L67 and L82,
as determined by our computational model of inhibitor binding. (B) TH92-5 has
the same structure as L82-G17, except the linker has been changed. (C) TH532-2-11 represents a construct that could theoretically overlap with the binding
site and conformation of both L67 and L82.

From here, I believe the best course of action would be a new CADD
screen against this verified inhibitor pocket. The current molecules have not
insignificant solubility issues, and as mentioned previously, the N-N bond(s)
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within L67 and L82 could present significant obstacles if these drugs are to be
developed with an eye on therapeutic possibilities. To this end, proposed inhibitor
TH95-2 (Fig. 23C) has had its hydrazone linker replaced with a urea based one,
and may be a potential candidate for future examination. Another option is a
pharmacophore based approach, which abstracts information about docking
compounds, instead of docking actual chemicals, (Horvath 2011, Sanders,
Barbosa et al. 2012) which is what I have done. Pharmacophore based
screening has already been used to identify potential ligase inhibitors, (Krishna,
Singh et al. 2014) but has not been utilized to examine the L82 binding site
identified here (Howes 2017).

Final Remarks

My graduate work started with evaluating LigI phosphorylation by mass
spectrometry, and testing Rad50 inhibitors. After two years in Baltimore, the lab
moved to Albuquerque, New Mexico, where I transitioned into the work on DNA
ligase inhibitors that is presented here. I would like to again thank Alan
Tomkinson for accepting me into his lab, and for his support over these past
years.
This year, 2017, is the 50th anniversary of the discovery of the first DNA
ligase. Since then, there have been significant advances in our collective
knowledge of their structure and function. Since then, over 50 structures of
ligases have been published. DNA ligases are critical to cellular viability, during
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DNA replication, a ligase
interacts with PCNA and
fully encircles DNA during
ligation, a mockup of which
can be seen in Figure 24,
(Pascal, O'Brien et al.
2004) the exact orientation
and mechanism of
interaction has yet to be
determined. The
information that was
gleaned from the crystal
structure alone is
remarkable, and further
biochemical, biological and

Figure 24. Ligase I and PCNA
A mockup of how PCNA and DNA ligase I might
interact during ligation. LigI is shown in the same
colours as in Figure 1, red DBD, greed AdD, and
yellow OBD. PCNA is shown in orange, and p21,
(Levin, Bai et al. 1997) which binds to PCNA at the
same location as LigI’s PIP box, is shown in blue.
(PDB ID’s used: 1AXC, 1X9N, 1BNA (Drew, Wing
et al. 1981, Gulbis, Kelman et al. 1996, Pascal,
O'Brien et al. 2004)).

structural studies will invariably advance our understanding of how ligases
operate. The predisposition to cancer in DNA ligase I-deficient mice highlights
the importance of understanding how these proteins coordinate and regulate
each other to maintain genome integrity. The ability to harness this information
and design specific inhibitors represents a potentially powerful tool, both as a
research tool, and as a therapeutic. I am confident improved inhibitors will be
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developed, either by improving on the current generation of ligase inhibitors, or
by using the identified L82 binding site to design novel ones.

Materials & Methods

Chemicals

The chemicals L67 (IUPAC: 2-[(3,5-dibromo-4-methylphenyl)amino]-N'-[(2hydroxy-5-nitrophenyl)methylidene]acetohydrazide), L82 (IUPAC: 4-chloro-5-{2[(4-hydroxy-3-nitrophenyl)methylidene]hydrazin-1-yl}-2,3-dihydropyridazin-3-one,
and L82-G17 (4-chloro-5-{2-[(3-hydroxyphenyl)methylidene]hydrazin-1-yl}-2,3dihydropyridazin-3-one) were done as described previously (Howes 2017).
Nanoparticle protocells were developed and kindly provided by the lab of Dr. Eric
Carnes.

MarvinSketch v.14.9.8.0 (ChemAxon (http://www.chemaxon.com)) was
used for drawing chemical structures. Tanimoto similarity scores were calculated
using the online tool ChemMine (Backman, Cao et al. 2011). All figures were
made using a combination of Microsoft PowerPoint (version 16.0.6965.2117) and
InkScape (version 0.92.0).
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Cell Lines

Human liver (HEP3B) cancer cell lines were acquired from Dr. Walker
Wharton at the University of New Mexico, and were grown in Dulbecco's Modified
Eagle's Medium (DMEM), purchased from Corning Inc. supplemented with 10%
fetal bovine serum (FBS) as well as the antibiotics penicillin and streptomycin. All
cells were incubated at 37°C and 5% CO2.

Protein Purification

Rosetta2 cells were transformed with plasmid DNA containing an
ampicillin resistance gene, as well as C-terminal PKA-target, his- and flag-tagged
LIG1 (Fig. S5A). An initial 2 mL culture in CircleGrow media (MP Biomedicals)
containing ampicillin and chloramphenicol was scaled up to 250 mL and grown at
37°C. When the culture OD600 was measured at or around 0.7 cells were
transferred to a 16°C. After 30 minutes at 16°C cells were induced with 0.2 mM
iso-propyl-thio-galactooside (IPTG) for 16 hours. Bacteria were pelleted and
lysed in 40 mM HEPES pH 7.5, 200 mM NaCl and 10% glycerol, plus protease
inhibitors. Cell debris were removed by high-speed centrifugation, clarified lysate
was loaded onto a 5 mL HisTrap HP column (GE Healthcare Life Sciences), and
proteins were eluted by increasing concentration of imidazole stepwise. Ligase I
containing fractions were purified using a HiTrap Q HP column (GE Healthcare
Life Sciences), and eluted via NaCl. This procedure yields a high purity ligase
with minimal degradation (Fig. S5B). Eluted ligase I fractions were pooled,
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concentrated using a 50 kDa MWCO centrifugal filter (EMD Millipore), and stored
at -80°C until needed. Figure S5A was generated using Serial Cloner, software
version 2.6.1 (http://serialbasics.free.fr/Serial_Cloner.html).

Measuring Solubility

The solubility of L67 and L82 was measured in 100 mM solutions of Tris,
HEPES, and PBS were made up at pH’s of 7.2, 7.5, and 7.7, deionized water
and 100% DMSO were used as controls. Precipitation was easily identifiable at
10x magnification. Each solution was examined under a microscope every 10
minutes for precipitation.

Compound Docking

The likelihood of small molecules to bind to DNA ligases was evaluated in
silico using the OpenEye suite of software, VIDA, Make Receptor, Omega and
OEDocking. The licenses for this software was used as part of collaboration with
committee member Dr. Tudor Oprea’s lab. Small molecules were generated in
SMILES format using MarvinSketch (version 14.9.8.0), using an academic
license. For any situation in which multiple stereoisomers were possible, all were
used. Chemical binning and hierarchical clustering was done using the online
tool ChemMine as well as calculation of Tanimoto similarity scores, and Figures
were rendered with PyMol (version 1.3) (DeLano 2002). Small molecule
structures were consolidated using VIDA (version 4.2.1), and multiconformers of
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every small molecule were generated using Omega (version 2.5.1.4), with a
maximum of 500 conformations per molecule. These multiconformer files were
used by the FRED (Fast Rigid Exhaustive Docking) function of OEDocking
(version 3.0.1) to predict each compound’s ability to interact potential receptor
sites on a given protein. Receptor sites were generated using Make Receptor
(version 3.0.1), generally using 2-3 amino acids to define the potential receptor
site. The results of the docking assay were exported as a spreadsheet, for
combination and analysis in Microsoft Excel 2013 (version 15.0.4797.1003).

Cell Proliferation

HEP3B cells were cultured in 96-well plates with ligase inhibitors or 0.5%
DMSO alone for five days at 37°C for use in an MTT assay. In the MTT assay, a
tetrazolium dye, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, is
metabolized into (E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3-diphenylformazan in the
mitochondria, during which its colour changes from yellow to purple. Cells were
incubated with the MTT reagent (Promega) for one hour at 37°C according to the
manufacturer’s instructions. Absorbance at 570 nm was measured using a plate
reader (PerkinElmer Victor 3V1420 Multilabel Counter). Cell viability is expressed
as percentage of the value obtained with DMSO-treated cells.

Toxicity in bacteria was measured by growing in-house E. coli bacteria
strain HI-1006 that had been transformed with the ampicillin containing plasmid
pUC19. Plasmid DNA was generously provided by the lab of Dr. Osley of the
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UNM Cancer Research Center. Cells were picked from a plate and grown in
ampicillin containing circle grow media, before being divided into 1 mL cultures.
The optical density at 600 nm (OD600) was used to measure cell growth, and was
measured hourly. DNA ligase inhibitors, L67, L82, L189, and L82-G17, were
tested at 100µM; hydrogen peroxide and 1% DMSO (vehicle control) were used
as position and negative controls, respectively.

Cosmic Database

Data was accessed 1/28/2017 (Forbes, Beare et al. 2015).
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Appendix – Supplemental Figures

Supplemental Figure 1. Small-molecule inhibitors identified by computer
aided drug design.
Previous work by the Tomkinson group published ten compounds that inhibit
DNA ligase I, but not T4 ligase (Chen, Zhong et al. 2008, Zhong, Chen et al.
2008).
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Supplemental Figure 2. Cells lacking LigI are more sensitive to L82 and
L82-G17.
(Data in Figure 8 was kindly generated by Dr. Annahita Sallmyr. The data
presented here represents the data that I produced prior to that which was
submitted for publication in DNA Repair.) Survival of wild-type (PF20) and
LIG1 null (PFL13) MEFs treated with (A) L82 or (B) L82-G17 for six days (*p<0.05, **- p<0.01, ***- p<0.005) was measured as described in Materials and
Methods. Results of at least three independent assays are shown graphically.
γH2AX formation measured by flow cytometry in wild-type (PF20) and LIG1
null (PFL13) MEFs incubated for 4 h (C) L82 or (D) L82-G17. Results of three
independent assays are shown graphically. (E) The increase in γH2AX was
also observed by immunofluorescence, following four hours of L82-G17
exposure.
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Supplemental Figure 3. Purity of ligation substrate oligos.
Each oligonucleotide, named TH_01, TH_02, and TH_03, were ordered from
IDT as unpurified oligonucleotides and purified in house on a urea sequencing
gel. Each oligo was then 32P labeled and run again on a sequencing gel, to
assess purity.
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Supplemental Figure 4. L67 is not effected by DNA in silico
The predicted position and conformation of L67 binding does not change
when modeled in the presence (lighter magenta) or absence (darker
magenta) of DNA.
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Supplemental Figure 5. 32P labelable, His- and Flag-tagged DNA
ligase I.
(A) Map of the plasmid used to express LigI that was labeled for DNA
pulldown assays. (B) Results of two column purification of LigI.
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